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Abstract
Premature death from cardiovascular disease is common amongst adult patients with 
chronic renal failure (CRF). The implication for paediatric patients, the majority o f whom 
now survive into adulthood, is that they maybe similarly affected but at an earlier age. 
Children with CRF already show signs of arterial disease in the absence of classical risk 
factors. The aim of this research was to develop ways of improving the outcome for 
children with CRF by investigating the effect of interventions on vascular function. 
Vascular endothelial function, which is dependent on nitric oxide (NO) (an antiatherogenic 
substance) can be measured using a non-invasive technique o f high resolution ultrasound. 
Abnormal responses represent the earliest change in the pathogenesis o f vascular disease 
and may be reversible. Bioavailability of NO may be reduced in CRF due to low levels of 
precursors, increased levels o f inhibitors and increased oxidant stresses.
The hypotheses examined were:
1) Dietary supplementation with L-arginine (the substrate for NO synthetase) improves 
large vessel endothelium-dependent vasodilatation and NO bioavailability.
2) Dietary supplementation with folic acid reduces homocysteine levels and improves large 
vessel endothelium-dependent dilatation.
3) Haemodialysis improves large vessel endothelium-dependent dilatation by lowering 
homocysteine levels, removing inhibitors of NO synthesis, reducing oxidative stress and/or 
removing free radicals.
Methodology was double blinded, randomized and placebo controlled in children with 
stable CRF in the absence o f classical risk factors for atherosclerosis. Endothelial function 
was measured in the brachial artery. Biochemical measures of NO activity and oxidant 
stress were also measured, along with the acute effect of haemodialysis on endothelial 
function.
We demonstrated that L-arginine was not beneficial as a therapeutic agent. Folic acid 
improved vascular function and is now used routinely in all children with CRF at Gt 
Ormond St Hospital. Haemodialysis had an adverse effect on vascular function-an 
observation that needs further study as the process in itself may contribute to the 
development of atherosclerosis.
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Chapter one 
Introduction
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1.1 Epidemiology
1.1.1 Cardiovascular mortality, the size of the problem
Premature cardiovascular disease amongst adult renal failure patients represents a major 
cause of mortality and morbidity, some 10 to 40 times that of the general population. 
Nowhere is this more striking than in the younger age group.
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Figure 1.1: All-cause cardiovascular mortality for men and women in the general 
population and in individuals receiving haemodialysis (1)
This is of increasing concern in the paediatric renal failure population (considered to be 
<16 years) as most are now surviving into adulthood, both because of advances in dialysis 
and transplantation and because treatment is being extended to the youngest patients.
12
1.1.2 Prevalence
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Figure 1.2: Prevalence of RRT paediatric population in the UK population (2)
The prevalence of the paediatric population receiving renal replacement therapy (RRT) (ie 
dialysis and renal transplant) has increased between 1992 to 2002, from 38.8 pmp to 52.4 
pmp (2). The better survival o f patients taken on at a younger age and increasing take on 
rates are responsible.
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The distribution of ages for 2002 are shown in figure 1.3. The rising numbers in each age 
group reflects the survival of younger patients and comparatively higher take on rates in 
the 12 to 15 years age group. The fall off in the older age group is due to transfer to adult 
units. The large proportion of male patients is due to increased incidence of obstructive 
uropathies such as posterior urethral valves and renal dysplasia.
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Figure 1.3: Age and sex distribution of the UK RRT in paediatric renal units in 2002 (2)
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1.1.3 RRT modality
Renal replacement therapy consists of haemodialysis (HD), continuous ambulatory and 
cycling peritoneal dialysis (CAPD and CCPD), and renal transplantation both cadaveric 
(Cad) and live related (LRD). The distribution of these modalities for 2002 is as shown in 
figure 1.4.
H LRD
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Figure 1.4: Current modality of RRT in paediatric units in April 2002 (2)
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1.1.4 Take on rates of patients on to RRT programmes (incidence of end stage renal 
failure)
Take on rates have changed relatively little but there is a general upward trend also 
contributing to the size o f the population.
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Figurel .5: New patients starting RRT in paediatric units in the UK from 1996 to 2002 (2)
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1.1.5 Survival
Years after presentation with ESRF
Figure 1.6: Survival analysis for patients starting RRT from April 1996 to March 2001 (2).
Five year survival for patients on RRT is 92%, although this is lower in infants (66%). 
Deaths are mostly due to dialysis access failure, infection and co-morbid conditions 
(usually in association with other congenital anomalies). With this generally good outcome 
we can only expect the size o f the paediatric RRT group to increase further.
The long term mortality and morbidity in this group of renal failure patients is uncertain 
but they may be expected to have similar vascular complications as the adults but at an 
even earlier age. It has been demonstrated that children with chronic renal failure already 
show signs of early vascular damage (3). This is in the absence of classical risk factors for 
atherosclerosis such as hypertension, chronic fluid overload, and abnormal lipid profiles 
thus suggesting a “uraemic” factor responsible for the phenomenon.
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1.2 Occurrence and pattern of cardiovascular death in CRF
1.2.1 Introduction
Death from cardiovascular related illness in renal failure is endemic and far exceeds that of 
matched population. Increased rates o f 10 to 40 times have been reported. This pattern has 
not changed between 1974 and 1990, despite advances in RRT, and a known association 
between renal failure and premature death from cardiovascular disease (4,5).
This is of increasing concern with a reported growth of the adult end stage renal disease 
(ESRD) group of up to 70% in the last decade (6).
Nowhere is the increased risk of death from cardiovascular disease more striking than in 
the young haemodialysis population. Patients less than 35 years are 500 times more likely 
to die from vascular causes than their healthy peers (1). Although the incidence of 
established renal failure amongst children is fairly constant there has been a significant 
increase in the prevalence over the last 10 years. With more infants being offered dialysis 
and improved survival o f children on RRT it is extremely likely that the effects of 
prolonged exposure to uraemic toxins will be associated with an increase in atherosclerotic 
morbidity and mortality similar to that seen in the adult population but occurring at an 
earlier age.
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1.2.2 Adults
Studies in adults, both retrospective and prospective, have consistently demonstrated 
increased rates o f cardiovascular mortality in renal failure patients (1, 5-10). Post mortem 
studies show that the presence of atherosclerotic disease in the conduit arteries of 
haemodialysis patients far exceeds that seen in non-uraemic individuals (8, 11). Death rates 
from myocardial infarction (MI) are reported at five times that of a control population and 
have an increased associated mortality (7). Peripheral vascular disease and cerebrovascular 
also more common (5, 12, 13).
This phenomenon of increased cardiovascular mortality was first noted in 1974 in 
haemodialysis patients and it was initially concluded by Lindner that the dialysis process 
itself was to blame (4). However it is thought that the atherosclerotic process begins much 
earlier. Indeed even a serum creatinine at 116pmol/l was found to be associated with 
increased risk of stroke and 130pmol/l with MI in a large prospective study. This is even 
after correction for traditional cardiovascular risk factors (14). This has been confirmed in 
a 10 year survey in adults with more significant CRF (creatinine clearance 30-35 
mls/min/1.73m2) where a three fold risk of both MI and stroke were demonstrated (12). In 
the elderly (>65 years) a linear relationship was confirmed between glomerular filtration 
rate (GFR) and the incidence of cardiovascular events (15).
The reasons for these repeatedly reported increased rates in adults is thought to be related
to two main factors: firstly the demographic changes in the dialysis population, ie
increased age and primary aetiologies of renal failure ie diabetes; secondly the increased
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prevalence of risk factors in the CRF population as compared with the general population. 
These were identified by the Framingham Study in the non-uraemic population as 
hypertension, lipid disturbances, left ventricular hypertrophy and glucose intolerance (16). 
In a prospective study examining comparative mortality from cardiovascular disease 
hypertension was seen in 63%, hypercholesterolaemia in 9%, cardiomegaly in 33% and 
diabetes in 13% of patients entering a dialysis programme. In addition 34% were smokers 
and 12% had suffered a previous MI or angina (10). Also, Culleton identified that mild 
CRF (serum creatinine 136-265 pmol/1) was not only common in the general population, 
but was associated with a high prevalence of co-existing cardiovascular disease (17).
It is clear that a lot o f the burden of CVD is related to the presence o f risk factors but what 
about an additional role o f uraemia itself and how early does the process begin?
1.2.3 Children
The understanding that the process o f atherosclerosis begins early in life was probably first 
realized in 1953 from post mortem studies among soldiers (whose average age was 22 
years) killed in action in North Korea. In 77.3% of cases some gross evidence o f coronary 
atherosclerosis was found (18). This is a rather shocking statistic in what might be 
expected to be a relatively fit group of men. Further postmortem studies have shown that 
the initial fatty streaks, an early feature o f atherosclerosis may be found after the first few 
months of life and increase in prevalence with age (19, 20).
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Figure 1.7: Fatty streaks in the aorta
Further evidence that the process has begun long before adulthood and may infact be 
preprogrammed is that low birth weight is associated with impaired endothelial function (a 
process in the development of atherosclerosis) in the first decade of life, even before major 
exposure to classical risk factors (21). These abnormalities persist into adult life (22). It is 
therefore thought that another process is at work unrelated to the traditional risk factors.
With the development of non-invasive techniques the findings o f post mortem studies can 
be further investigated in vivo, looking for evidence of atherosclerosis and identifying risk 
factors both classical and non classical, for example, obesity and type 1 diabetes in 
children is associated with arterial abnormalities in vivo (23, 24).
Prospective population studies in children have identified predictors of atherosclerosis in 
later life. Low density lipoprotein-c (LDL-c) levels and body mass index (BMI) in the 
Bogalusa Heart Study (486 children) (25), LDL-c, systolic BP, BMI and cigarette smoking 
in the Young Finns study (2229 children) (26) were identified as predictors using 
measurement of carotid intima-media thickness (a marker of preclinical atherosclerosis).
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Less traditional risk factors have been identified in similar studies in children. These 
include elevated homocysteine in children with hypertension and fibrinogen levels in obese 
children (27) and an adipose derived protein adiponectin (28).
With regard renal failure populations evidence exists that the process maybe “ accelerated” 
in both CRF and dialysis patients. Histological evidence was rather dramatically 
demonstrated by Nayir et al when they examined internal iliac artery segments o f 12 
children (11-17yrs) obtained at the time of renal transplantation. Five showed fibrous 
intimal thickening, two had micro calcification of the intima and two already had 
atheromatous plaques (29).
In vivo evidence has been demonstrated with impaired endothelial function seen in 
paediatric renal transplant patients (30) and perhaps what is of most relevance, in children 
with CRF and no classical risk factors (3). Endothelial studies in young adults (20-40years) 
with childhood onset CRF have confirmed the presence of subclinical atherosclerotic 
disease (31).
1.3 Arterial disease in CRF
1.3.1 Plaque morphology
There has been a concept of “accelerated atherosclerosis” initially observed in 
haemodialysis patients in 1974 to account for the increased mortality amongst renal failure 
patients. This was attributed to the process of haemodialysis rather than renal failure itself 
but some work has shown there is no relationship between time on haemodialysis and
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increased risk (32) and that the vascular abnormalities predate initiation of dialysis (9, 32- 
34).
In 1979 it was noted that the large elastic arteries had marked intimal hyperplasia and 
striking medial calcification (11). This has been supported by further post mortem studies 
in adults which have shown heavy calcification in plaques (without any increase in the 
frequency of distribution) as compared to the mostly fibroatheromatous type seen in non- 
uraemic individuals (35). This may explain why an “accelerated” process is involved as 
these plaques behave differently as exemplified by high reocclusion rate within one year of 
70% in uraemic patients compared to 40% in diabetics and 20% in non diabetics following 
percutaneous coronary angioplasty (36).
Figure 1.8: Histology of coronary arterial calcified atheromatous plaque in uraemia. Note 
increased intima media thickness and calcified areas (appear blue).
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These observations of increased media thickness and calcification have formed the 
foundation of many of the non-invasive investigations used in both adults and children 
with CRF.
Electron-beam computerized tomography can determine the presence of arterial 
calcification in the coronary arteries that correlates well with the extent and severity of 
angiographic lesions (see paragraph 1.5.3.2). Haemodialysis patients aged 20-30 years 
have been shown to have significant coronary artery calcification compared with controls 
and younger dialysis patients (37). We know however that it does exist in younger patients 
as demonstrated in vivo in the internal iliac arteries by Nayir et al with a mean age of 15 
years (29).
Intima-media thickness as measured by B mode ultrasound has also been used as a tool to 
monitor vascular pathology and can be used to predict cardiovascular mortality. Increased 
values have been seen in both predialysis and dialysis patients.
1.4 Endothelial physiology and pathophysiology
1.4.1 Normal abnormal and pathophysiology
It has become evident that the vascular endothelium, the single cell layer lining all blood
vessels, is crucial in the control of vascular physiology. It has been recognised to be one of
the body’s largest and most complex organs with an overall weight similar to the liver. The
endothelium separates the vessel wall from circulating components o f blood and plays a
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pivotal role in the defence against atherogenesis.
The endothelium regulates vascular tone, vascular smooth muscle cell proliferation, 
inflammation, permeability, cell adhesiveness and coagulation. It responds to a number of 
stimuli including neurotransmitters released from autonomic and sensory nerves 
(acetylcholine, norepinephrine, ATP, substance P), circulating hormones (catecholamines, 
vasopressin, angiotensin II, insulin) and locally active autocoids produced both by 
endothelial and smooth muscle cells (bradykinin, adenine nucleotides and nucleosides, 
angiotensin and endothelin). In addition, the endothelium responds to physical stimuli, 
including changes in shear stress, which elicits flow-mediated vasodilatation (FMD).
1.4.1.1 Vascular tone
In response to these various stimuli, endothelial cells produce a variety of vasoactive 
substances, both constricting and dilating. Nitric oxide (NO) was identified initially as an 
endothelial relaxing factor (EDRF) following the observation of vasodilatation in isolated 
arteries after infusion of acetylcholine (38). Six years later this EDRF was discovered to be 
the freely diffusible gas, NO (39). It is continually produced in the endothelial cells by 
nitric oxide synthetase (eNOS), which incorporates molecular oxygen into the substrate L- 
arginine producing NO.
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Figure 1.9: Conversion of L-arginine to NO and citrulline by NOS with BH4 as co-factor
NO diffuses readily through cells to act in the vascular compartment and on nearby 
vascular smooth muscle cells where it activates guanylate cyclase and increases production 
of cyclic 3 ’, 5’guanosine monophosphate (cGMP). cGMP in turn reduces intra-cellular 
calcium within smooth muscle cells, and results in smooth muscle relaxation.
Endothelial NOS binds to distinct domains of the plasma membrane called caveolae, which
Stimulus
Endothelial cell
Co2Veol«odulin
c itru ll in e
Smooth mu«cle cell
guanylate cyclase
Figure 1.10 Endothelial cell NO production
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are tethered to the cytoskeleton. Increased intracellular calcium facilitates calmodulin 
formation, which displaces the caveolin to activate the enzyme. This reaction is dependent 
on the presence o f tetrahydrobiopterin, BH4. Stimuli that increase intracellular calcium 
levels include receptor-mediated agonists, such as acetylcholine, bradykinin, substance P 
and the physical stimulus of endothelial cell shear stress. Thus these stimuli result in 
vasodilatation.
Other vasodilator substances produced by the endothelium are arachidonic acid derivatives 
(prostacyclins) and endothelium derived hyperpolarising factor (EDHF).
The effects of these relaxing factors in continually counterbalanced to varying degrees by 
vasoconstricting factors. These are thromboxane A2, superoxide anion, angiotensin II, and 
endothelins. The endothelins are a family of peptides which mainly act on smooth muscle 
cells to bring about vasoconstriction but a small number stimulate NO and prostacyclin 
release thus providing a feedback mechanism.
The specific contributions made by each of these mediators to the endothelium-dependent 
regulation o f vascular tone are both species and tissue dependent with the main players 
being NO and endothelin.
1.4.1.2 Smooth muscle cell proliferation
In the presence o f healthy endothelium smooth muscle cell turnover remain static. This is 
due to a balance of growth promoters, angiotensin II, endothelin, and platelet derived 
growth factor with inhibitors such as heparin, NO and transforming factor-P (TGF p). If
the endothelium is denuded under experimental conditions proliferation is the dominant
27
process producing a neo intima.
1.4.1.3 Control of permeability
The intact endothelium is able to control the passage of solutes, water and cells across its 
surface. Pores exist for water and solutes but the passage o f larger molecules and proteins 
is controlled by a dynamic actin filament system at intercellular junctions. Some 
endothelial factors will increase permeability and others will reduce it. During the 
inflammatory process leucocytes will cross the barrier. This is controlled by adhesion 
molecules (intercellular adhesion molecules, ICAM and vascular cell adhesion molecules, 
VC AM) expressed on the surface of the endothelial cell.
1.4.1.4 Haemostasis
Endothelial cells both inhibit platelet aggregation via NO and prostacyclin and provide a 
non thrombogenic surface due to their ability to inactivate factor X and thrombin in 
addition to activating protein C through binding thrombin.
1.4.2 Endothelial function and atherosclerosis
An impaired or abnormal response of the endothelium is termed “endothelial dysfunction” 
and is generally characterised by impaired bioavailability o f NO, the main participant in 
maintaining a healthy endothelium. Inhibition of NO production in experimental animal 
models causes accelerated atherosclerosis (40). Endothelial dysfunction has been widely 
shown to be the earliest clinically detectable pathological process leading to the 
development of atherosclerotic disease (41-43).
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It has been repeatedly demonstrated that endothelial dysfunction exists in the form of 
abnormal endothelial dependent responses (to chemical or mechanical stimuli) in coronary, 
conduit and resistance vessels both in patients with established clinical atherosclerosis and 
in those at risk of atherosclerosis. These include hypertension diabetes, coronary artery 
disease, cigarette smoking, increasing age and hypercholesterolaemia (44-48).
Of importance it has been noted that the presence of endothelial dysfunction in conduit 
vessels correlates well with the presence of established atherosclerotic disease in the 
coronary circulation (49, 50).
It also is a predictor o f subsequent development of clinically significant disease. In patients 
with mild coronary artery disease, the presence of coronary endothelial dysfunction (using 
acetylcholine) was associated with a major cardiac event over a 28 month follow up period 
(51). This finding was confirmed in another study with a 7.7 year follow up. It was also 
noted that coronary endothelial function was an independent predictor even after 
adjustment for traditional cardiovascular risks and established disease (52).
The prognostic value of endothelial dysfunction of the forearm conduit arteries (as oppose 
to coronary vessels) has been demonstrated in untreated hypertensive patients where 
impaired responses are a predictor o f cardiovascular events including stroke and 
myocardial infarction (53).
These studies suggest that detecting endothelial function is important as it may allow 
intervention with therapeutic options before atherosclerosis is established.
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1.4.3 Endothelial Dysfunction in CRF
Animal studies have demonstrated that experimentally induced uraemia can impair 
acetylcholine (Ach) induced vasodilatation ie bring about endothelial dysfunction (54, 55).
In adult humans endothelial dysfunction has been demonstrated using endothelial 
dependent stimuli such as Ach and sheer stress models in both chronic and endstage renal 
disease (both haemodialysis and peritoneal dialysis) on repeated occasions (32, 33, 56-58). 
In these patients many of the traditional risk factors associated with atherosclerosis are 
present such as smoking, diabetes and hypertension.
In addition endothelial dysfunction has been demonstrated also to have a predictive value 
when considering all cause mortality in end stage renal disease (59).
Studies in children with CRF might overcome this hurdle of confounding factors in search 
for a uraemic factor that may be responsible for the excess deaths from cardiovascular 
disease in this group. A study by Kari et al showed that in children with CRF who were not 
hypertensive, diabetic or smokers and had normal total cholesterols that endothelial 
function was impaired when compared with matched controls (3).
This may be due to reduced bioavailability of NO as a consequence of reduced availability 
of substrate, increased levels of inhibitors, and increased removal of NO.
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1.5 Assessment of endothelial function and abnormal arterial pathophysiology
1.5.1 Introduction
The ability of the endothelium to respond normally can be tested in vitro or in vivo by 
using endothelial dependent stimuli and comparing them to endothelial independent 
stimuli. In vivo tests can also be subdivided into invasive and non-invasive. In addition the 
characteristic histopathological abnormalities of the arterial tree in renal failure has led to 
the development of other non-invasive techniques to assess extent o f early subclinical 
cardiovascular disease.
1.5.2 In vitro
Isolated vessels such as mesenteric artery are placed in organ baths and mounted on 
myographs. Their response to acetylcholine (endothelial dependent dilator) and sodium 
nitroprusside (endothelial independent dilator, ie donor of NO) are recorded and compared. 
Animal experiments by Kakoki and Ruschitza demonstrated impaired endothelial function 
in the aortic and renal arteries using rat models of acute renal ischaemia (54, 55).
1.5.3 Invasive in vivo techniques
Invasive in vivo techniques include venous occlusion plethysmography, which is based on
the observation that vasodilatation of the forearm microvasculature is associated with a
proportional increase in blood flow into the forearm. An upper arm occluding BP cuff is
inflated sufficiently to occlude venous return, but insufficient to impair arterial filling.
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Arterial blood continues to enter, and forearm volume expands. The rate o f arterial blood 
flow into the forearm is proportional to the rate of rise in forearm volume. Strain gauges 
are attached to the forearm to measure forearm blood flow from changes in forearm 
circumference. The effects of various pharmacological agents on blood flow can be 
examined in particular endothelial dependent dilator agents (acetylcholine, bradykinin) can 
be compared with endothelial independent agents such as glyceryl trinitrate (GTN) when 
looking for evidence of endothelial dysfunction. London et al used this technique to 
demonstrate an impaired response in haemodialysis patients, which was also found to be 
an independent predictor o f all cause mortality over a 60 month follow up period (59).
Good correlation between stain gauge plethysmography and flow mediated dilatation of 
the brachial artery exists (60).
During coronary angiography the measurement of Doppler blood flow velocity in the 
coronary arteries in response to endothelial dependent stimuli such as acetylcholine, 
increased blood flow using papaverin and cold pressor testing, can be used to assess 
endothelial function. This technique was used to demonstrate that although the coronary 
arteries in patients with hypercholesterolaemia were angiographically normal endothelial 
dysfunction was present (42).
1.5.4 Non-invasive in vivo techniques
Invasive techniques are not practical when carrying out large scale investigations and 
studies on children. The phenomenon of endothelial function fortunately lends itself well
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to assessment by non-invasive methods and these more recently have become the main 
stay of investigation into endothelial dysfunction, particularly in children and young adults.
1.5.4.1 Flow mediated dilatation
Flow mediated dilatation (FMD) uses a high resolution, external ultrasound assessment of 
conduit arterial vasculature, usually the brachial artery. It was developed in 1989 and is 
based on the observation that the stimulus of flow produces dilatation in the arteries (61).
Flow,
Dilatation
Time
Figure 1.11: Relationship between blood flow and vessel dilatation
This process is endothelial dependent and was shown to be in part NO dependent (62, 63). 
Vascular activity in response to endothelial dependent stimuli, increased flow, is contrasted 
with an endothelial independent stimulus, systemic glyceryl trinitrate which is a direct 
donor of NO. Arterial diameter is measured at rest and following a brief period of reactive 
hyperaemia produced by suprasystolic inflation of a cuff distal to the site of measurement. 
The percentage change in brachial vessel size is recorded. This is then compared with the 
endothelial independent stimulus, GTN, given sublingually which assesses the integrity of 
the smooth muscle response. The two recordings are compared. Impaired responses using 
this technique have been found in some high risk adult groups such as, patients under 40 
years with coronary artery disease (50), CRF (33), haemodialysis and peritoneal dialysis
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patients (57, 58). In children, impaired endothelial dependent responses have been found in 
obesity and type 1 diabetes (23, 24, 64, 65). Of particular interest is the study by Kari et al 
who noted an impaired response in children with CRF of 4.9 % compared to 8.9% 
(p=0.0001) in matched controls where endothelial independent responses were similar 
(25.1 % v 23.3% (p=0.31) (3). This has also been demonstrated in renal transplant children 
with stable graft function (29).
Endothelial dependent response Endothelial independent response
%
P<0.001
12
10
8
6
4
2
ControlsCRF
GTN
%
30
25
20
15
10
5
P=0.31
CRF Controls
Figure 1.12: Impaired endothelial function demonstrated in children with CRF (3)
1.5.4.2 Other non invasive methods of assessing abnormal arterial pathophysiology 
As discussed earlier the pathophysiology of atherosclerosis in renal failure is characterised 
by vascular calcification, which leads to structural and functional disturbances in the 
arterial tree. This manifests itself by reduced arterial compliance and arterial wall 
thickening. Techniques o f pulse wave velocity (PWV), intima-media thickness (IMT) and 
electron beam computerised tomography (EBCT) have been employed as they detect such 
abnormalities and have been shown to be significant predictors of cardiovascular mortality 
(66).
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Pulse wave velocity
Arterial stiffness is characteristic of atherosclerosis. Wada et al demonstrated a clear 
association between arterial stiffness (as measured using the relationship between vessel 
diameter and its change with blood pressure) and the presence of atherosclerotic lesions 
seen in the same subjects at postmortem (67). The technique o f pulse wave velocity (PWV) 
has been developed as a more direct method of assessing arterial stiffness. This is the 
measurement o f the velocity of the pulse wave when traveling between two sites of the 
arterial tree (usually common carotid and femoral arteries) using transducers connected to 
an automated on line calculating device. An increased value indicates increased stiffness of 
the arterial segment being observed. It has been demonstrated to be both reliable and 
repeatable. In addition, aortic PWV in hypertensive (both treated and untreated) 
individuals is not only strongly associated with the presence and extent of atherosclerotic 
disease (defined on the basis of clinical events) but it has also been demonstrated that even 
a single recorded value of >13m/s is a strong predictor of cardiovascular mortality (68).
Arterial stiffness has also been demonstrated in ESRD population on haemodialysis (69). 
Shinohara found that the presence of predialysis renal failure was also significantly 
associated with increased aortic PWV, independent of age, gender, blood pressure, BMI, 
smoking, and adverse lipid profiles and that infact haemodialysis had a favourable effect 
on arterial stiffness with reduced values seen when compared with predialysis patients 
(70). Even in young patients (<55 years) with mild to moderate renal failure a negative 
correlation exits between PWV and creatinine clearance independent o f blood pressure and 
classical cardiovascular risk (71).
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In addition to this, the predictive power of PWV is also applicable to the dialysis 
population. PWV, in addition to age and time on dialysis in a prospective trial was 
demonstrated to be better than pulse pressure or left ventricular mass at predicting 
cardiovascular mortality (72).
It has therefore been considered a valuable tool when carrying out large scale observational 
and interventional studies o f the clinical effectiveness of therapies.
Intima-Media Thickness
Arterial IMT (carotid, femoral) is an index of thickening of the arterial wall.
Using B-mode high resolution ultrasound this can be measured reliably. It is an 
independent predictor of cardiovascular mortality in nonuraemic individuals after 
adjustment for traditional risk factors (66). In hypercholesterolaemic children studies have 
demonstrated increased carotid IMT compared to controls (73, 74). As autopsy changes 
suggest that the first atherosclerotic lesions develop in the abdominal aorta. Jarvisalo et al 
in 2001 studied the distal aortic IMT in addition to carotid IMT. They discovered that in 
addition to significantly greater IMT in the high risk children (hypercholesterolaemic and 
type 1 diabetics, n=60, aged ll±2yrs) than in the controls, there was a relatively larger 
difference in aortic IMT than carotid IMT in the high risk group. They suggested therefore 
that aIMT was the best non-invasive predictor of preclinical atherosclerosis in children 
(75).
Using this technique in the uraemic population increased carotid IMT is seen in both CRF 
predialysis patients 0.889±0.035 versus 0.68510.01mm in controls p<0.001 (34) and 
haemodialysis patients (76).
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Electron Beam CT
High resolution transverse images of the heart are obtained and a cumulative calcification 
score is generated for all the coronary arteries.
Figure 1.13: EBCT image showing calcification of left coronary artery 
The extent of coronary artery calcification (CAC) as measured by EBCT correlates with 
the extent and severity of angiographically documented lesions in the non-uraemic 
population (77, 78, 79) and with previous myocardial infarction (80). This has been found 
to have a predictive value for coronary events in asymptomatic individuals but the 
relationship to clinically significant lesions remains controversial (81). Calcification was 
found in 88% of young patients (20-30 years) with CRF on dialysis and almost absent in 
matched controls (82). Medial calcification may be responsible as EBCT is not capable of 
distinguishing between intimal and medial calcification so the higher calcification scores 
may reflect the media wall changes rather than purely intimal changes. Haydar et al 
examined the relationship between CAC and coronary artery disease in the 46 uraemic 
patients. They discovered that as in the non-uraemic population there was a strong 
correlation between the extent of coronary artery disease as demonstrated by coronary 
angiography and CAC score as measured by EBCT. Further more by multivariate 
regression analysis they showed that CAC score was the only predictor of burden of 
coronary artery disease in their study population (83).
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1.6 Risk factors for atherosclerosis in CRF
1.6.1 Introduction
Many adults with CRF also have the traditional risk factors for cardiovascular disease such 
as diabetes, hypertension, smoking, dyslipidaemia (10, 17). The purpose of this thesis is to 
examine the effect of CRF per se on the development of atherosclerosis. Here the key to 
endothelial dysfunction is thought to be impaired bioavailability of NO. This may be due 
to reduced levels of substrate, impaired production or increased inactivation. In addition 
factors relevant to CRF are high homocysteine levels, increase oxidant stress, abnormal 
calcium phosphate metabolism and anaemia.
1.6.2 L-arginine
The semi-essential amino acid L-arginine is the only substrate for NO synthesis. Serum 
levels of L-arginine have been reported as being low in CRF but this is not a universal 
finding. The intra-cellular concentrations of L-arginine far exceed the Km value for NO 
synthase (NOS) making it unlikely that it is simply L-arginine concentrations which are the 
rate limiting step for NO production. It has been demonstrated that high but physiological 
levels of LDL may affect cellular uptake of L-arginine and hence NO production (84).
1.6.3 Accumulation of endogenous inhibitors of NO synthase
In CRF decreased clearance results in high levels of circulating analogues of L-arginine,
asymmetrical dimethylarginine (ADMA) and its stereoisomer, symmetrical
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dimethylarginine, SDMA (85). ADMA has been characterised as an endogenous inhibitor 
of NOS, the enzyme which catalyses the production of NO from L-arginine in vascular 
endothelial cells (86). ADMA acts by competitively displacing L-arginine from its binding 
site on NOS. This is even at concentrations seen in patients with CRF. ADMA levels have 
also been shown to have a predictive value when considering cardiovascular mortality in 
dialysis patients (87) and to be positively associated with carotid artery IMT in non­
dialysis patients (88). Currently a prospective trial is looking at the prognostic value in an 
unselected group as elevated levels are also seen in patients with cardiovascular disease, 
hypertension, chronic heart failure and hypercholesterolaemia (89).
1.6.4 Hyperhomocysteinaemia
The observation in 1969 that patients with congenital defects of homocysteine metabolism 
resulting in hyperhomocysteinaemia (levels >50pmol/l nr 5-15pmol/l) die from premature 
vascular disease led to the investigation of homocysteine as causal in the pathogenesis of 
atherosclerosis. High levels have subsequently been noted in high risk populations 
including CRF in adults (90) where there is an inverse relationship to GFR (91). Elevated 
levels have also been noted in children with CRF and on dialysis (92-94).
One possible mechanism therefore for endothelial damage in CRF is the presence of high 
circulating levels of homocysteine. Homocysteine is a sulphur containing amino acid 
formed as an intermediate during the metabolism of methionine. It has been shown in 
population studies to be an independent risk factor for both vascular disease (95, 96) and 
myocardial infarction (97, 98). In CRF, homocysteine is also an independent risk factor
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(99) and in dialysis patients, hyperhomocysteinaemia is more prevalent than traditional 
cardiovascular risk factors (100).
In vitro and in vivo studies suggest that homocysteine causes endothelial dysfunction 
either directly or via intermediate reactions increasing oxidised LDL levels (101) and 
hence increased rates of NO inactivation. This is supported by studies, which have shown 
the effects of acute hyperhomocysteinaemia on endothelial function can be reversed with 
vitamin C (102) and that NO dependent flow mediated dilatation is impaired in 
hyperhomocysteinaemia (103). It is thought also to have a directly toxic effect on the 
endothelium, to increase platelet aggregation and smooth muscle proliferation. Even 
modestly elevated homocysteine levels may be particularly damaging in the presence of 
the atherogenic risk profile of CRF (104).
1.6.5. Increased oxidant stress
Many cell types in vivo, continuously form reactive oxygen species, primarily as a result 
of energy production. These are a family of molecules, including molecular oxygen 
produced by all aerobic cells. At physiological concentrations they are necessary for 
normal cell function such as signaling and cell growth. They are mostly free radicals (ie 
have an unpaired electron) such as superoxide (O2 -) and hydroxyl (HO-) and include nitric 
oxide (NO). Other reactive oxygen species include hydrogen peroxide (H2 O2 ) and 
peroxynitrite. These as are not free radicals in that they do not possess unpaired electrons, 
but still have oxidizing effects.
In health there is a balance between the production of these molecules and counter activity
of antioxidant systems. Overproduction of reactive oxidant species overwhelming
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antioxidant defence is referred to as a state of increased oxidant stress and can occur in 
response to inflammation, infection, environmental pollutants and malignancy. The result 
of which is the oxidative damage o f DNA, lipids, proteins and carbohydrates.
Oxidised lipids for example can be mutagenic and cytotoxic, particularly to the 
endothelium. In addition it has been demonstrated that oxidised lipids can affect 
endothelial NOS expression and hence NO production (105). Increased oxidant stress also 
produces activation o f oxidant responsive genes leading to production o f growth factors, 
chemokines and adhesion molecules that enhance the inflammatory response (106).
It is therefore no surprise that oxidant stress is thought to be a key factor in the adverse 
vascular biology seen in hypertension, diabetes, heart failure and hypercholesterolaemia.
____________________ Effects of reactive oxygen species____________________
Reduced BH4 levels 
Increased ADMA levels 
Peroxidation of lipids 
Inhibition of cGMP 
Increased platelet aggregation 
Increased expression of endothelial cell adhesion molecules 
Increased expression of platelet derived growth factor on smooth muscle cells 
_______________________ Oxidative damage o f DNA_______________________
Table 1.1: Summary of the effects of reactive oxygen species
Superoxide dismutase (SOD) is part o f the intracellular antioxidant system enzyme found 
in both the cytoplasm and mitochondria, which mops up superoxide. NO can be inactivated
by superoxide ions and stabilized by SOD. Catalase/glutathione
peroxidase 
SOD y
202.-+2H+---------> O2+H2 O2 2H202  > 02 +2 H20
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As there is a much faster reaction rate between NO and superoxide than between SOD and 
superoxide there is always likely to be some inactivation of NO but under physiological 
conditions antioxidant defences will minimise it. In pathological situations o f excess 
superoxide the reaction between superoxide ions and NO is the dominant pathway 
resulting in the formation of peroxynitrite. Peroxynitrite at low concentration has similar 
actions to NO but at high concentrations it is a potent cytotoxic agent causing protein 
fragmentation by nitration of amino acids such as tyrosine residues to form nitrotyrosine. 
These are found in excess in atherosclerotic plaques in humans.
The role o f  LDL
It has been shown that under conditions of increased, but still physiological concentrations 
of native LDL and oxidised LDL, that there is a conformational change in endothelial NOS 
(eNOS) which promotes generation of superoxide in preference to NO. This was partly 
inhibited by the addition of L-arginine and suggested that LDL affects uptake of L-arginine 
(84). Also Wever et al also observed that during hyperlipidaemia eNOS might contribute 
to oxidative stress by a reduction in tetrahydrobiopterin (BH4) dependent NO formation 
(107). These support several other studies which have shown that in the absence of L- 
arginine or tetrahydrobiopterin eNOS can produce superoxide and H202.This has been 
referred to as NOS uncoupling (108).
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Figure 1.14: Pathways of increased oxidant stress
Oxidant stress and CRF
There is evidence that renal failure is a state of increased oxidant stress. This is through 
indirect evidence with raised levels of oxidised lipids, markers of lipid peroxidation (109, 
110), lowered measured total antioxidant activity (111) and increased level of antibodies to 
oxidised LDL (112). Antibodies to oxidised LDL have been demonstrated to have an 
independent predictive value of cardiovascular mortality in dialysis patients (113).
Low levels o f NO metabolites have been measured in the urine of CRF patients suggesting 
that NO production is down-regulated and that oxidative stress may be increased (114).
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The presence o f oxidant stress (using oxidatively modified amino acids and plasma 
proteins) has been shown to be present even at GFR of 60ml/min and showed no 
correlation with the degree o f renal failure below this (115).
The relationship between oxidative stress and endothelial function in CRF (mean 
creatinine clearance 25mls/min) was investigated by Annuk et al who confirmed that CRF 
was a state of elevated oxidative stress with reduced LDL lag times (a measure of LDL 
resistance to oxidation), reduced total antioxidant activity of the serum and increased diene 
conjugates, (markers of lipid peroxidation). These markers correlated with impaired 
endothelial function suggesting that this was an important mechanism for the development 
o f cardiovascular disease in this population (116).
1.6.6 Reduced antioxidant capacity
Antioxidant defences counterbalance the production of reactive oxygen species by 
preventing free radical formation, blocking chain reactions and repairing oxidative 
damage. They may be intra or extra cellular, proteins, enzymes or vitamins either obtained 
from the diet or naturally present within cells.
Glutathione (GSFI) is the primary nonenzymatic cellular antioxidant system found in all 
cellular compartments. Vitamin E is a family of lipid soluble compounds (tocopherols) and 
resides in plasma lipoproteins and cell membranes where it is best placed to prevent lipid 
peroxidation. Vitamin C takes part in the regeneration of vitamin E by scavenging free 
radicals. Antioxidant enzyme systems consist of SOD, the absence o f which is lethal,
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catalase and glutathione peroxidase. These all convert free radicals to less reactive forms. 
For example glutathione peroxidase detoxifies hydrogen peroxide to water.
Extra cellular antioxidants consist of proteins such as transferrin, albumin, urate and 
ceruloplasmin.
Total antioxidant capacity has repeatedly been demonstrated as low in CRF. There is 
evidence that the activity of the enzymes SOD, catalase and glutathione peroxidase are 
reduced and that levels o f antioxidant vitamins are low (116-120). Annuk showed that 
there were reduced levels of GSH (the most important cellular antioxidant) and increased 
levels o f oxidised glutathione (GSSG) in renal failure compared to normal controls (116). 
Children with CRF (5-18 years) have been shown to have reduced SOD and glutathione 
peroxidase activity in addition to reduced levels of co-factors for theses enzymes such as 
selenium and copper. The degree of antioxidant capacity was related to the severity of the 
CRF (121).
Some studies have shown acute benefit of antioxidant vitamin supplementation in states of 
endothelial dysfunction such renal failure (122).
1.6.7 Abnormal phosphate, calcium and parathyroid hormone (PTH) metabolism.
In renal failure disturbances of calcium and phosphate metabolism are common. These
changes include raised plasma calcium and phosphate levels, secondary
hyperparathyroidism, reduced synthesis of active vitamin D metabolites, reduced
expression of calcium receptors and the use of vitamin D derivatives and calcium
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supplements. Evidence suggests that these abnormalities may contribute to the 
development of vascular dysfunction and calcification (123). Cardiovascular morbidity and 
mortality correlates with abnormalities of calcium and phosphate metabolism. 
Hyperphosphataemia predicts reduced survival due to excess cardiovascular mortality in 
haemodialysis patients. Individuals in the highest quintile for plasma phosphate had a 52% 
greater risk o f death from coronary artery disease, 39% greater risk of stroke, 34% greater 
risk of death from other cardiac causes and a 26% increased risk of sudden death compared 
to those in the lowest quintile (124). Vascular calcification as detected by EBCT in young 
adults (20-30 years) on dialysis was higher in those with greater calcium phosphate 
product (37).
The mechanism for this increased mortality in altered calcium phosphate metabolism is 
likely to be due to not only calcification o f the arterial tree but also calcification o f cardiac 
valves, myocardium and left ventricular hypertrophy (LVH). LVH is not only very 
common in renal failure, up to 41% in adult predialysis patients, (125) but has also been 
reported as an independent risk factor for cardiac mortality with two thirds of dialysis 
patients with LVH dying of heart failure or sudden death (126).
Major positive associations with the development of LVH have been hypertension and 
anaemia (127), which may be self-explanatory, but also PTH is thought play a leading role. 
PTH in vitro has both inotropic and chronotropic effects on cardiomyocytes (128). Of 
more interest perhaps is that cultured ventricular myocytes exposed to PTH increased 
protein synthesis indicating a trophic effect causing interstitial fibrosis (129). 
Parathyroidectomy has been shown to improve left ventricular function (130).
46
1.6.7 Anaemia
Anaemia has been reported as an independent risk factor for cardiac disease and mortality 
(131). A doubling of the risk of death has been seen in patients with Hb<8g/dl compared 
with those >11 g/dl (132). However the use of recombinant erythropoietin has been 
effective in reducing mortality in haemodialysis patients (133) and producing regression of 
left ventricular hypertrophy in both dialysis and CRF patients (134).
Adverse effects o f increasing the haematocrit using erythropoietin was noted in 
haemodialysis patients over 65 years with clinically evident cardiac disease by Besarab et 
al (135). This highlights the possible pro-hypertensive effect o f erythropoietin.
1.6.8 Dyslipidaemia
Dyslipidaemia in CRF is characterised by an accumulation o f triglyceride-rich VLDL, IDL
and LDL remnants with reduced concentrations o f cardioprotective HDL as a result of
reduced tissue lipase activity. These abnormalities progress with renal impairment (136).
Cholesterol concentrations are similar to those seen in the healthy general population and
may even be lower. This is often a reflection o f malnutrition. Normal or low cholesterol
concentrations often mask an abnormal lipid sub-fraction profile, which has an excess of
pro-atherogenic small dense LDL particle. These are more susceptible to oxidation and
have a higher cholesterol content (137). Oxidised LDL is toxic to the endothelium and can
broach the intima. It can inhibit endothelial dependent vasodilatation and induce apoptosis
of endothelial cells. This abnormal triglyceride/cholesterol ratio is due to reduced activity
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of the enzymes which control lipoprotein degradation.
Levels of Lipoprotein (a), a large apoprotein associated with LDL particles are raised in 
early renal impairment as a result o f excess production. They are pro-atherogenic and are 
an important predictor o f cardiovascular morbidity in the general population (138). Lp(a) 
accumulates in the vascular wall at sites of atheroma formation and is also prone to 
oxidation
1.6.9 Inflammation
Inflammation has been identified as an important process in the initiation and progression 
of atherosclerosis. The earliest lesion, the fatty streak is a pure inflammatory lesion 
consisting of monocyte derived macrophages and T- lymphocytes. This process is thought 
to be initiated by some sort of toxic injury such as oxidised-LDL, which could affect NO 
production resulting in endothelial dysfunction. The inflammatory response via cytokines, 
chemokines and growth factors stimulates the migration of and proliferation of smooth 
muscle to form an intermediate lesion. Eventually through repeated accumulation of 
mononuclear cells and the formation of fibrous tissue an advanced complicated lesion is 
formed consisting o f a fibrous cap with a core o f lipid and necrotic tissue.
Acute phase proteins are proteins that change in concentration by at least 25% in 
inflammatory disorders.
CRP is an acute phase protein the concentration o f which alters by 1000 fold in 
inflammation and has been identified as a predictor of cardiovascular mortality in non- 
uraemic populations (139). Elevated CRP levels have been found in dialysis patients in the 
absence of infection (140) and in predialysis patients even those with a GFR of up to
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59mls/min (141, 115). More importantly these elevated levels have been found repeatedly 
to be an independent predictor of all cause morbidity in CRF (142-146).
1.7 Theoretical therapies
1.7.1 L-arginine
It is widely accepted that the earliest changes in the development of atherosclerosis are at 
the level of the endothelium. The intact healthy endothelium produces NO which is the 
main player in antiatherogenesis (Section 1.4). It is therefore conceivable that by 
increasing NO production the process of atherosclerosis may be attenuated or even 
reversed. As L-arginine is the only substrate for NO production it could be hypothesized 
that by supplementing with L-arginine, NO production could be enhanced. Kanno et al in 
1992 showed that L-arginine increased urinary metabolites o f NO and cGMP which would 
support this theory (147).
There are several ways in which supplementation with L-arginine might influence the 
bioavailability o f NO particularly in CRF: it may correct substrate deficiency the kidney is 
the main source of L-arginine (148), overcome competitive antagonism due to ADMA, and 
increase production to overcome rapid removal due to increased oxidative stress. 
Experimentally in animals L-arginine has been used to inhibit atherogenesis in 
hypercholesterolaemic rabbits by inhibiting platelet activation (149) and improve 
endothelial dependent vasodilatation, firstly by Cooke in 1992 (150) and subsequently by 
Jeremy in 1996 (151).
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Dietary L-arginine supplementation in humans has already been shown to improve 
endothelial function in the brachial artery of young people with hypercholesterolaemia
(152): reduce the adhesiveness of mononuclear cells in hypercholesterolaemic humans
(153): improve endothelial responses associated with raised ADMA (154): improve 
coronary small vessel endothelial function and symptoms (155) and improve symptoms in 
patients with heart failure (156).
In the setting o f animal studies of CRF (the 5/6 nephrectomised rat) L-arginine has been 
shown to ameliorate glomerulosclerosis although the mechanism was initially not 
examined (157). Subsequently it was shown by Ashab et al that L-arginine had not only a 
beneficial effect on CRF by improving creatinine clearance and reducing proteinuria but 
that it also restored NO production which was initially lower than in controls (158).
In renal failure studies in adults results have been variable. Hand used an acute infusion of 
L-arginine to restore predialysis endothelial function to the better postdialysis values 
suggesting that haemodialysis improves endothelial function by increasing NO 
bioavailability (159). Cross et al found no benefit of acute L-arginine on chronically 
impaired endothelial function in haemodialysis patients (160). De Nicola et al assessed the 
effect of oral L-arginine on NO production in CRF and found no benefit, measuring 
urinary cGMP levels (161). Prior to my studies L-arginine had not been used as a 
therapeutic tool in renal failure patients but had been used subsequently in children with 
chronic kidney allograft dysfunction on cyclosporin to assess its effect on proteinuria and 
renal function (162).
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L-arginine is thought also to mediate beneficial effects on vascular biology as it is capable 
of reducing total homocysteine levels by increasing NO production. NO coverts 
homocysteine to an antioxidant and vasodilatory compound, S-nitrohomocysteine (163).
1.7.2 Folic acid
Homocysteine levels are an independent predictor of cardiovascular mortality both in the 
general population and in CRF. Folic acid has been shown to lower homocysteine in non- 
uraemic individuals (164) and uraemic adults (90, 165) and children (94), by increasing 
tissue methylation of homocysteine to form methionine. This is true even in the presence 
of normal folate level. Homocysteine can also be metabolized to cysteine as part of the 
transulfuration pathway, which requires the co-factor vitamin B6.
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Figure 1.15: Homocysteine methionine pathway (the sulphur containing amino acid 
pathway).
It may be postulated that by lowering homocysteine levels a beneficial effect on the 
development of cardiovascular disease could be seen.
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In studies in adults with hyperhomocysteinaemia and familial hypercholesterolaemia folic 
acid supplementation has resulted in not only a lowering o f homocysteine but 
improvement in endothelial function (166-168). In 36 children (mean age 13.6yrs) with 
type 1 diabetes, 5mg folic acid improved FMD by 2.58% (169). This was independent of 
total homocysteine levels which were not elevated at the start o f the study, suggesting an 
additional direct benefit on endothelial function.
Folic acid levels (or indeed B12) are not reported to be low in CRF, even in children and 
there is no correlation between the vitamin levels and homocysteine levels. Infact levels of 
folic acid were high in one study, possibly due to impaired clearance as they were highest 
in the dialysis patients (170).
In CRF it appears therefore that there maybe a relative resistance to folic acid or that serum 
levels do not reflect intracellular levels.
The active metabolites of folic acid such as methyltetrahydrofolate (MTHF) have been 
more successful at lowering homocysteine in CRF dialysis patients (171). However this is 
not a consistent finding. A similar dose was given to a larger group of 50 dialysis patients 
and showed no superiority over folic acid (172). The same group had shown earlier no 
extra benefit from supplementing with B12 or B6, essential co-factors (173).
In addition to the above mechanism folates are postulated to increase concentrations of
tetrahydrobiopterin, which is an essential co-factor in the production of NO. This was
thought to be the mechanism of improvement in endothelial function seen in
hypercholesterolaemics as a fall in superoxide production was noted in vitro (174).
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The impact on endothelial function in adults with CRF, on haemodialysis or peritoneal 
dialysis has however been disappointing (175,176,177). This maybe due to the likelihood 
of established vascular disease, the presence of multiple risk factors and because 
supplementation rarely reduces homocysteine levels to within the normal range (175).
1.7.3 Anti-oxidants
Antioxidant vitamins, by scavenging free radicals could theoretically increase NO 
bioavailability by protecting NO from inactivation by free radicals.
Animal studies have demonstrated that anti-oxidants can improve endothelial dependent 
dilatation (178) and this effect has also been observed in human clinical studies.
1.7.3.1 Vitamin C
Vitamin C is the primary water-soluble antioxidant in human plasma and early 
epidemiological studies showed that Vitamin C levels correlated inversely with 
hypertension and cardiovascular disease (179). It has also been demonstrated that 500mg 
of Vitamin C can significantly lower blood pressure in hypertensives (180). It may 
therefore follow that it could improve vascular biology in the setting of endothelial 
dysfunction. Vitamin C, when given acutely to hypercholesterolaemic individuals (181) 
and patients with coronary artery disease (182) produced a beneficial effect on endothelial- 
dependent function not seen on endothelial independent function or normal volunteers. 
More sustained, chronic administration (4 weeks) of Vitamin C in hypertensive individuals 
by Duffy et al showed no benefit on endothelial function in adults with hypertension (183).
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In children with familial hypercholesterolaemia chronic administration of vitamin C and E 
improved FMD (184).
In the renal setting, vitamin C was first used in renal transplant patients. Endothelial 
dysfunction was demonstrated to be independent of uraemia, hypertension and treatment 
with cyclosporine (185). Williams et al (186) used 2g o f vitamin C given acutely to 
improve endothelial function. This was associated with an increased resistance o f the 
serum to oxidation, thus supporting the idea that the beneficial effect was through 
antioxidant capacity and that the pre-existing adverse biology may be due to increased 
oxidative stress. This effect has been transferred to the haemodialysis population where 
benefit was seen in the resistance vessels but not conduit vessels and was mediated by 
increased NO bioavailability (187).
This beneficial effect is thought to be due to free radical scavenging playing a significant 
role in regulation of intracellular redox states (188), prevention o f oxidation of LDL (189) 
and increasing prostacyclin concentration (190).
1.7.3.2 Vitamin E and beta-carotene
Other antioxidant vitamins include vitamin E and Beta-carotene. These are lipid soluble. 
Vitamin E inhibits lipid peroxidation of LDL by scavenging lipid peroxide radicals and the 
carotenes by scavenging peroxy radicals. As oxidative modification o f lipids is key for the 
development of atherosclerosis, defects in this system may predispose to adverse vascular 
biology.
Animal studies have shown that supplementation with vitamin E in hypercholesterolaemia
can attenuate the development of atherosclerosis (191, 192). Epidemiological studies by
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Rimm, Stampfer and Kushi examining the relationship between heart disease and vitamin 
intake according to diet and supplements suggest that vitamin E may be cardioprotective 
(193-195). Prospective clinical intervention studies in man have been less consistent, some 
have shown benefit (196, 197) where others have not (198) but Vitamin E given for 4 
weeks to 7 subjects with hypercholesterolaemia did show a beneficial effect on NO 
production (199).
Levels of lipophyllic antioxidants have been found to be low in haemodialysis patients 
(200) and Vitamin E coated dialysers used in haemodialysis reduce oxidative stress and 
reversed the adverse effect of non biocompatible dialyser on endothelial function (201). A 
prospective study (SPACE) by Boaz et al demonstrated that Vitamin E reduced composite 
CVD and MI in adults on haemodialysis (202).
1.7.4 Statins
Clinical studies have shown that the use of statins (HMG-CoA reductase inhibitors) to 
lower cholesterol reduces the risk of cardiovascular events (203, 204). In addition to the 
direct effect of lipid lowering these drugs are thought to have a beneficial effect on 
endothelial function (205). Indeed this effect has been demonstrated in patients with 
coronary artery disease (206), normocholesterolaemic healthy volunteers (207) and post­
menopausal women both without any change in lipid profile (208). This effect was also 
found to be sustained in an 18 month study of FMD in patients on statin therapy (209).
The mechanism of this effect may be by potentiated NO production as in the studies by
Mercuro et al the effect was blunted by L-NMMA, an inhibitor of NO production (208).
Statins are also thought to confer benefit by suppressing inflammation. Dalla Nora et al
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showed that statins lower markers of leucocyte adhesion in type II diabetics (210). Other 
potential mechanisms are a direct antioxidant effect (demonstrated in vitro), an 
antithrombogenic effect, and inhibition of both smooth muscle proliferation and uptake of 
LDL into monocytes leading to the formation of the foam cell. The major culprit in the 
formation of the atherosclerotic plaque (211).
As chronic renal failure patients have adverse lipid profiles (high Tg, LDL, IDL reduced 
HDL, but with normal or low cholesterols, which separates them from the aforementioned 
groups) and are in a state of chronic inflammation with increased oxidative stress, statins 
could potentially be used to improve vascular morbidity and endothelial function. They 
have been shown to improve lipid profiles in CRF (212) and more importantly result in 
long-term reductions in cardiovascular mortality and all cause mortality (213). Benefits in 
endothelial function as measured by FMD have been seen in renal transplant patients with 
hypercholesterolaemia (214).
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Figure 1.16: Adjusted Kaplan-Meier survival curves for all cause mortality in 
haemodialysis patients (from 213)
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On going prospective studies (CHORUS) in haemodialysis patients are examining the 
potential mechanisms o f vascular damage by measuring inflammatory proteins (ICAM, IL- 
6, monocyte chemoattractant protein) and markers o f cardiac muscle pathology (troponin I 
and T) in addition to cardiovascular morbidity and mortality (215).
The use of statins in children was originally associated with concerns about adverse effects 
on growth. When simvastatin at 40mg was used in 173 children with familial 
hypercholesterolaemia, no adverse effect on growth or pubertal development was 
demonstrated over a 28 week follow up (216). A further study in 50 children (nine to 
eighteen years) showed in addition to beneficial effects on lipid profiles, improvement in 
endothelial function as measured by FMD (217). Their use in children with CRF has not 
been investigated.
1.7.5 Other theoretical therapies
Other theoretical therapies include plant sterols. These have been used safely to lower LDL 
levels but did not improve endothelial function in children (5-12yrs) with familial 
hypercholesterolaemia (218).
ACE inhibitors in adults on haemodialysis have been shown to increase serological 
markers of antioxidant defences (219). ACE inhibitors are not licensed for use in children 
but could potentially improve endothelial dysfunction.
Erythropoietin is a glycoprotein hormone produced by the kidney that promotes
proliferation and differentiation of erythrocyte precursors. A recombinant form has been
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developed and is in regular use to treat the anaemia associated with CRF. Overall treatment 
is beneficial but a major adverse side effect is hypertension and in investigating the 
mechanism for this it has been discovered that it is capable, in vitro, of up-regulating NO 
production (two to four fold) by increasing inducible NOS transcription in the normal 
endothelial cells in culture (220). However, in aortic segments from rats with CRF no such 
benefit was seen and those treated with erythropoietin had an augmented hypertensive 
response (221). It maybe however therefore that some o f the beneficial effects are 
mediated by its potential to overcome increased oxidant stress provided its use is not 
accompanied by hypertension.
Tetrahydrobiopterin is a necessary co-factor for the production of NO by endothelial NOS. 
It can be given orally and has been shown to improve endothelial function in adults with 
hypercholesterolaemia (222). Studies in acutely induced ischaemic renal failure in animals 
showed that impaired endothelial function could be restored by oral tetrahydrobiopterin 
when given both before and after the injury (54). This suggests it may potentially be of 
benefit in endothelial dysfunction in humans with CRF.
1.8 Nature of the studies
It has already been demonstrated that the process of atherosclerosis begins in childhood in 
the presence of CRF. Impaired endothelial function, the earliest detectable change in the 
process of atherosclerosis, was seen in the absence of classical risk factors. This has two 
main implications. Firstly that atherosclerosis is likely to develop early in this group, 
which is expanding; and secondly that this may be the period when the process is
reversible and therapies should be considered.
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Studies in this thesis examined possible therapeutic interventions and investigated them in 
children with stable chronic renal failure. In addition the possibility that in the end stage 
renal disease population, the process of haemodialysis itself was atherogenic was 
examined.
1.9 Hypotheses
The original hypothesis are therefore
1.9.1 Dietary supplementation with L-arginine (the substrate for NO synthetase) improves 
large vessel endothelium-dependent vasodilatation and NO bioavailability.
1.9.2 Dietary supplementation with folic acid reduces homocysteine levels and improves 
large vessel endothelium-dependent dilatation.
1.9.3 Haemodialysis improves large vessel endothelium-dependent dilatation by lowering 
homocysteine levels, removing inhibitors of NO synthesis, reducing oxidative stress and/or 
removing free radicals.
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Chapter Two 
The subjects
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2.1 Introduction
Children with CRF and those requiring dialysis provide an ideal model to study the 
pathogenesis of atherosclerosis in renal failure. In all adult studies confounding variables 
make interpretation of the results difficult in addition to the fact that the presence of 
established vascular disease limits validity of the study of therapeutic interventions. In 
children not only does the absence of hypertension, diabetes, ischaemic heart disease and 
peripheral vascular disease provide a pure model o f renal failure, such that the “uraemic 
factor” can be studied but also vascular disease is generally not yet established making 
therapeutic intervention studies more valuable.
This chapter provides a summary of the clinical and epidemiological features of the study 
population.
2.2 L-arginine and folic acid study subjects
2.2.1 Selection
Subjects were recruited prospectively from the general nephrology clinics held weekly at 
Great Ormond St Hospital. Children were aged from 7 years in order that they could co­
operate with the study. Informed consent was obtained from the parents or guardians 
following an interview in which details of the study were explained and written 
information was given.
Inclusion criteria were children with stable CRF and an absence of the classical risk factors
associated with the development of cardiovascular disease (hypertension, diabetes,
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smoking, obesity and hypercholesterolaemia). Children with nephritic syndrome and those 
who were taking any vasoactive medication which may interfere with the study were 
excluded. Of the 25 recruited for the L-arginine study, 12 of them took part in the folic 
acid study in addition to 13 new subjects.
We did not preselect children on the basis of endothelial function in order that the study 
group should be representative of all children with moderate to severe CRF.
2.2.2 Characteristics
Thirty seven children (20 boys and 17 girls), mean age was 12±3 years (range 7-19 years) 
with stable CRF were studied.
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Subject Age
(yrs)
Sex Wt
(kgs)
Height
Cms
GFR
(mls/min)
Serum
creatinine
(pmol/L)
Aetiology of 
CRF
L-arginine study
1 RS 14 M 59.5 156.0 25 214 Reflux and 
dysplasia
2 CL 14 F 48.0 160.0 34 160 Dysfunctional
bladder
3 FH 13 F 35.0 143.0 10 538 Single kidney, 
megaureter
5 SK 13 M 35.0 133.0 38 170 PU Valves
6 MM 14 M 50.0 170.0 48 130 PU Valves
7 JR 10 M 34.0 134.0 34 165 Reflux
8 MW 14 M 34.1 150.5 10 500 PU valves 
Single kidney
9 BC 13 M 34.0 144.0 15 384 Dysplasia
10 CJ 14 M 51.5 152.5 41 117 Dysplasia and 
reflux
11 BW 9 M 22.0 121.5 19 276 PU valves
12 AS 13 M 47.0 148.5 34 105 PU valves
13 MJ 14 F 63.0 164.1 30 147 Reflux
14 JB 13 M 47.0 152.4 34 105 PU valves
15 KV 12 F 43.0 134.5 40 108 Dysplasia
16 TP 15 M 47.7 170.3 48 99 Dysplasia
17 SS 19 M 64.5 173.0 9 747 Dysplasia
18 ZI 10 M 20.5 116.0 46 78 Cystic renal 
disease
19 CS 7 F 16.4 105.0 9 445 Cortical
necrosis
20 SH 7 F 22.1 120.0 25 180 Unknown
21a GC 7 F 19.0 114.0 29 102 Single kidney 
with
Pyelonephritis
21b AB 9 F 20.3 118.0 19 101 Dysplasia
22 DM 15 F 52.0 170.0 14 500 Reflux
23 ZG 11 M 36.0 146.5 48 103 PU valves
24 AC 15 F 60.9 160.0 10 650 Single Kidney 
with PUJ 
obstruction
25 KW 7 F 35.0 132.0 32 128 AR polycystic
kidney
disease
Table 2.1 A: Characteristics of study subjects (L-arginine)
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Subject Age
(years)
Sex Weight
(Kgs)
Height
(cms)
GFR
(mls/min)
Creatinine
(pmol/L)
Aetiology of 
CRF
Folic acid study
1 CH 11 F 22.2 120 10 233 Cystic renal 
disease
2 HJ 8 F 21.5 123.5 40 93 Renal vein 
thrombosis
4 EC 15 F 58.0 152.0 15 369 Dysplasia
8 KJ 14 F 58.5 155.6 41 109 Dysplasia
10 RF 8 M 20.5 120.0 35 92 Dysplasia
13 HW 12 M 24.5 135.0 19 219 Cortical
necrosis
14 JN 9 M 25.5 122.5 16 292 Dysplasia
15 MR 9 M 31.5 126.8 17 448 Dysplasia
16 JH 11 M 38.0 140.0 24 234 Reflux
21 LS 10 F 37.9 145.3 34 132 Dysplasia
23 JT 16 M 52.0 163.2 35 182 Dysplasia
25 ZQ 8 F 19.0 N/A 20 143 Unknown
Table 2. IB: Characteristics of study subjects (folic acid) 
2.3 Haemodialysis study subjects
2.3.1 Selection
Seven stable children receiving eulovaemic haemodialysis at Great Ormond St Hospital 
were entered into the study. Exclusion criteria were age <7 years (to ensure cooperation 
with the study), CRF o f inflammatory cause, diabetes, arterio-venous fistulae in both arms, 
significant arterial/venous stenoses in proximal blood vessels, concurrent medication with 
immunosuppressants, and those with inter-dialytic fluid gains.
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2.3.2 Characteristics
Seven children (3 boys and 4 girls, mean age was 12±3 years (range 8-17years) established 
on haemodialysis were studied.
Subject Age
(yrs)
Sex Wt
(kgs)
Aetiology of 
ESRF
Drugs Access Dialyser
1 13 M 42 Dysplasia Frusemide 
Nifedipine 
Atenolol 
Ca carbonate 
Onealpha
Permcath COBE500
2 8 F 36 Reflux Na
bicarbonate 
Na Cl
Ca carbonate 
Erythropoietin
Permcath COBE400
3 9 F 37.5 Congenital
Nephrotic
Onealpha 
Ca carbonate 
Erythropoietin
Permcath NIPRO
FP70
4 17 F 52.7 Reflux Nifedipine 
Atenolol 
Ca carbonate 
Onealpha 
Erythropoietin
Permcath COBE500
5 9 F 33.7 Dysplasia Ca carbonate Permcath COBE500
6 13 M 42.2 Wilms/Drash Ca carbonate 
Erythropoietin 
Folic acid 
Onealpha
AVF COBE500
7 15 M 80.5 Dysplasia Onealpha
Na
bicarbonate 
Ca carbonate
Permcath COBE500
Table 2.2: Characteristics of haemodialysis study subjects
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Chapter Three 
Common Methodology
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3.1 Introduction
Elements of the studies which are common to all will be discussed here. This therefore 
includes a description o f assessment of endothelial function using the technique of flow 
mediated dilatation (FMD), biochemical assays and statistics. The local ethics committee 
approved all the studies and informed consent was obtained from parents or guardians.
3.2. Measurement of endothelial function
3.2.1 Technique
Endothelial function was determined by recording the dilator response o f the brachial 
artery to increase blood flow generated during reactive hyperaemia o f the downstream 
forearm, flow mediated dilatation. Subjects lay supine in a temperature-controlled 
laboratory (22-25°C). The brachial artery was scanned in longitudinal section using a 7 
MHz linear array transducer and an XP 128/10 (Acuson), magnified using a resolution box 
function and gated with the R wave of the ECG.
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Cuff Ultrasound
probe
Figure 3.1 A: Diagrammatic representation of technique
3 .1 B: Photograph of the set up of the cuff and ultrasound probe
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Figure 3.2: Static ultrasound image view of brachial artery, showing digital calipers within 
the arterial lumen. The calipers mark the point where blood flow is recorded. The Doppler 
signal measuring flow for each cardiac cycle is also shown in the lower part of the image.
End-diastolic images of the vessels were acquired every 3 seconds using data-acquisition
software (Information Integrity, Boston, USA) and stored off-line for later analysis.
Arterial diameter over a 1-2 cm segment was determined for each image using automatic
edge detection software (Information Integrity, Boston USA). Analysis was performed by
an experienced vascular technician blinded to the phase of the study. Using pulsed wave
Doppler, blood flow was recorded continuously throughout the study and was expressed as
the velocity time integral (VTI; area under the blood velocity/time curve for a complete
cardiac cycle). Baseline recordings of arterial diameter were made for one minute before
inflation of a blood pressure cuff placed distal to the site of arterial imaging. Recording
continued for 5 minutes during cuff inflation to 300 mmHg and for 5 minutes after
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deflation. Endothelium-independent dilatation of the brachial artery was assessed by 
measuring the dilator response to a 25 pg dose o f the NO donor, glyceryl trinitrate given 
sublingually. This elicited vascular dilatation of the same order of magnitude as that of the 
endothelium-dependent flow stimulus. Results are expressed as percentage maximum 
change in vessel diameter from baseline.
3.2.2 Blood flows
As the stimulus is flow, we needed to ensure that this was standardized so that the response 
of brachial artery dilatation could be compared between subjects and within subjects at 
different time points.
The Doppler signal from the observed vessel was the velocity-time profile for a single 
cardiac cycle and is displayed as a Doppler curve. The area under the curve was the 
velocity-time integral (VTI), and approximates to the average distance traveled by a pulse 
of blood during one cardiac cycle and was expressed as metres.
As the area under the curve (VTI) = velocity (metres/second) x seconds, so VTI = metres. 
As volume of flow per minute is equal to the distance traveled multiplied by the cross- 
sectional area of artery and the heart rate, then VTI is proportional to volume flow since 
heart rate, the Doppler angle of incidence and arterial diameter remain essentially constant 
during the period of study.
Blood flow (VTI in m) produced by the cuff occlusion was recorded at baseline (5 seconds 
before cuff release), at the point o f cuff release and at 5, 15, 30, 45, 60, 75 and 90 seconds 
post release of the cuff.
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Figure 3.3 Examples of the Doppler curves from which flow (VTI=area under the curve) is 
calculated.
A: Pre release o f the cuff VTI=0.22m
B: A time point post release of the cuff, VTI=0.403m
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The peak of the increase in flow was recorded as maximum reactive hyperaemia and 
expressed as a percentage change from baseline.
0.3
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Time points
Figure 3.4: The change in blood flow recorded at the 9 time points.
3.2.3 Reliability and reproducibility
This technique has been reported to be both reliable and repeatable.
Sorensen et al investigated the possibility of error in the measurement of arterial diameter 
and noted using ‘phantom’ arteries that technicians were able to measure diameter 
correctly to within 0.04mm and could distinguish between pairs of phantom arteries with 
diameter differences 0.1 mm in 61% of cases (223).
Reproducibility in children aged 7 to 18yrs was investigated by Kari who recorded from 
analysis of variance a co-efficient of variation of 4.3% when measuring FMD on 3 
different occasions by the same observer (3).
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In adults Sorensen reported a co-efficient of variance for inter-observer repeatability of 
1.8% for 3 different observers (223).
3.3 Biochemistry
Blood samples were taken at the time intervals described in each study by myself, spun 
and frozen for batch analysis.
3.3.1 General biochemistry
Full blood count, urea, creatinine, bicarbonate and electrolytes were measured (Vitros 750, 
Ortho-Clinical Diagnostics, Rochester, NY). Fasting lipid analyses were performed for 
total cholesterol (TC), high-density lipoprotein (HDL) and triglycerides (TGs) using 
colorimetric assays (Vitros 750, Orthoclinincal). Both very low-density lipoprotein 
(VLDL) cholesterol and LDL were calculated. LDL subfractions were measured using 
high-resolution polyacrylamide gel electrophoresis (Quantimetrix, California) and reported 
as the ratio of less dense to more dense (LDLl+2:LDL3+4+5).
3.3.2 Measures o f oxidative stress
Various indirect measures o f oxidative stress have been developed and used extensively. 
Those used in the studies described in this thesis are, LDL lag times, total antioxidant 
activity, antibodies to oxidised LDL and lipid peroxides.
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LDL is susceptible to oxidation and oxidised LDL is key in the development of 
atherosclerosis. LDL lag times are an in vitro measure of LDL resistance to oxidation, and 
were measured by firstly isolating LDL from heparinised plasma using density gradient 
ultracentrifugation and desalted by gel filtration. Oxidation was promoted using copper 
chloride. The production of conjugated diene (markers of lipid peroxidation) was 
monitored using spectrophotometry. Lag times were calculated as the time intercept 
between the line of maximum slope of the propagation phase and the absorbance at 
baseline equaled zero (see figure 3.5) (224).
Total antioxidant activity is an overall measure of the serums antioxidant capacity. The 
assay is based on the horseradish peroxidase-catalysed oxidation of a chemiluminescent 
substrate, luminol by hydrogen peroxide. The production of the light signal depends on 
continuous production of free radicals from luminol and oxygen. The signal can therefore 
be suppressed by free radical scavenging. The suppression will last until the test serums 
capacity is exhausted and the light signal will return. The result is calibrated against a 
standard solution (225).
Absorbance
Absorbance at time=zero
Lag time (mins)
Figure 3.5: Method for determining lag time.
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Antibodies to oxidised LDL
Antibodies against oxidatively modified LDL can be used as a measure of oxidation 
processes occurring in vivo. Elevated values have been found in subjects with 
atherosclerosis and correlations have been noted to the progression of vascular disease 
(226).
Antibodies to oxidised LDL were measured directly using an ELISA technique in a pre 
prepared kit (Olab, Biomedica Gruppe, Germany). Copper oxidised LDL was used as the 
antigen.
Total plasma lipid peroxides (reaction products o f oxidative damage to lipids) by a lipid 
hydroperoxide assay kit (Cayman, San Diego).
L-Arginine and L-arginine analogues
Free L-arginine levels were measured by an automated amino analyser (Pharmacia, Milton 
Keynes, UK); plasma nitrite and nitrate (NO oxidation products) by chemi-luminescence; 
nitrated proteins (nitrotyrosines: NO and superoxide result in peroxynitrite, which 
combines with tyrosine residues and is present in atherosclerotic plaques) by competitive 
ELISA with nitrated human serum albumin as standard; and analogues of L-arginine, 
ADMA and SDMA by HPLC.
Folate levels and homocysteine
Serum and red cell folate levels were determined using radioimmunoassay (Abott IMx) 
with a normal range for serum folate of 2 to 20pg/L and red cell folate of 150 to 650pg/L. 
Plasma total (free and bound) homocysteine was measured using a competitive
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fluorescence polarization immunoassay (normal range 4.4 to 13.7pmol/l for adults, Abbot 
IMx).
3.4 Statistics
The null hypothesis states that the intervention (L-arginine/folic acid) will have no extra 
effect on endothelial function over placebo. The study size was based on a power 
calculation at 80%, significance value of 0.05 to show a 2% improvement in FMD. Each 
subject served as his or her own control.
The data were tested for normality using Shapiro-Wilk and modified Kolmogorov- 
Smirnov test.
All descriptive data are expressed as group mean ± standard deviation and significance is 
interpreted as a p value <0.05.
The primary study endpoint was the change in FMD (post-treatment value minus pre­
treatment value) on L-arginine/folic acid and on placebo. The change on L-arginine/folic 
acid was compared by paired Student t tests.
For the folic acid study a second analysis was performed, final FMD after folic acid and 
after placebo were compared using ANCOVA. All data were analysed for period and carry 
over effects.
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Within subject variation in physical parameters was analysed using repeated measures 
linear model. Baseline values before active agent or placebo and other outcome variables 
were also compared using linear regression.
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Chapter Four 
The L-arginine study
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4.1 Original hypothesis
Dietary supplementation with L-arginine (the substrate for NO synthetase) improves large 
vessel endothelium-dependent vasodilatation and NO bioavailability.
4.2 Introduction
Premature atherosclerosis is the most important cause of death in adults with chronic renal 
failure (CRF), and is believed to be due to a high incidence of the classical risk factors in 
this population (227) However, my group have previously demonstrated that conduit artery 
endothelial function is already abnormal in children with CRF even in the absence of these 
risk factors, suggesting a toxic effect of uraemia itself (3). Endothelial dysfunction is a key 
early event that precedes the formation of atherosclerotic plaques, and involves reduced 
bioavailability of nitric oxide (NO), an important anti-atherogenic agent (228). The semi­
essential amino acid L-arginine is the only substrate for NO synthesis. Levels of L-arginine 
have been reported as being low in CRF but this is not a universal finding (229).
In CRF however, decreased clearance results in high levels of circulating analogues o f L- 
arginine, asymmetrical dimethylarginine (ADMA) and its stereoisomer, symmetrical 
dimethylarginine, SDMA (85). ADMA has been characterised as endogenous inhibitor of 
NO synthase, the enzyme which catalyses the production of NO in vascular endothelial 
cells from L-arginine (86). Also, NO may be inactivated by increased oxidative stress and 
free radical production in CRF (see chapter 1.6). There are, therefore, several ways in 
which supplementation with L-arginine might improve the bioavailability of NO in CRF: it
may correct substrate deficiency; overcome competitive antagonism; and increase
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production to overcome rapid removal. Dietary L-arginine supplementation has already 
been shown to improve endothelial function in the brachial artery o f young people with 
hypercholesterolaemia (152) and experimentally to inhibit atherogenesis in animal models 
(150,151).
My hypothesis was that arginine supplementation might improve NO bioavailability and 
endothelial function, and therefore lead to a simple preventative treatment strategy to 
decrease the risk o f premature vascular disease. The technique of high-resolution 
ultrasound was used to measure endothelial function non-invasively by assessing the 
change in brachial artery diameter in response to endothelium dependent and independent 
stimuli, in a randomised, double blind placebo controlled cross-over trial of oral L-arginine 
supplementation in children with CRF.
4.3 Methods and subjects
Subjects 4.2.1
Twenty-five children (11 girls and 14 boys, mean age 12±3 years (range 7-17years)) with 
CRF (GFR <50ml/min/1.73m2) were studied. Twenty-four had congenital structural and 
one acquired (neonatal cortical necrosis) causes of CRF (see chapter 2). We did not 
preselect children on the basis of endothelial function in order that the study group should 
be representative of all children with moderate to severe CRF.
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4.3.2 Study design
The trial was randomised, placebo controlled, double blinded and cross over in design with 
two four-week treatment periods separated by a four-week washout period. Blood samples 
were taken following a 6 hour fast. L-arginine was given at 5g/m2 surface area to a 
maximum of 7 gms three times daily. This dose was selected to provide a two fold increase 
in plasma L-arginine levels and was based on previous studies performed by our group (8). 
After 3 children with low GFR complained of nausea and were found to have an elevated 
urea on completion o f the first treatment phase the dose of the treatment syrup was 
subsequently adjusted in those with a GFR < 35mls/min/l .73m2 to 2.5g/m2 three times 
daily (without unblinding the study). The active drug preparation and the placebo were 
prepared as syrup by South Devon Healthcare, Paignton, Devon TQ4 7TW. Dietary intake 
of nitrates and nitrites were not restricted as it was thought not to be practical in this age 
group and we anticipated poor compliance. As each child acted as their own control, it was 
not felt to be a confounding variable. However, this places limitations on the interpretation 
o f the nitrate/nitrite data.
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Children were evaluated at the start and end of each treatment period. At each visit, supine 
blood pressure was recorded, blood taken (after a 6 hour fast) and vascular function was 
assessed.
Visit I Visit 2 Visit 3 Visit 4
i  f  y r i f 1 r
Treatment Washout
A
T reatment
period one period
y
period two
'i r  i r y r  \  r
Week 0 Week 4 Week 8 Week 12
4.3.3 Assessment of vascular function
Endothelial function was determined by recording the dilator response of the brachial 
artery to increase blood flow generated during reactive hyperaemia of the downstream 
forearm, flow mediated dilatation (FMD). The technique is as described in chapter 3.2. 
Analysis was performed by an experienced vascular technician blinded to the phase of the 
study.
4.3.5 Laboratory assays
Urea, creatinine, bicarbonate and electrolytes were measured. Fasting lipid analyses were 
performed for total cholesterol (TC), high-density lipoprotein (HDL) and triglycerides 
(TGs). Both very low-density lipoprotein (VLDL) cholesterol and LDL were calculated. 
LDL subfractions were measured using high-resolution polyacrylamide gel 
electrophoresis. LDL lag times, lipid peroxides and antioxidant activity were measured as 
described in chapter 3.3.
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Free L-arginine levels were measured by an automated amino analyser; plasma nitrite and 
nitrate (NO oxidation products) by chemi-luminescence; nitrated proteins (nitrotyrosines: 
NO and superoxide result in peroxynitrite, which combines with tyrosine residues and is 
present in atherosclerotic plaques) and analogues of L-arginine, ADMA and SDMA by 
HPLC.
Power calculations were as described in chapter 3. The primary study endpoint was the 
change in FMD (post-treatment value minus pre-treatment value) on L-arginine and on 
placebo. The change on L-arginine and placebo was compared by paired Student t tests.
4.4 Results
4.4.1 Baseline characteristics
The clinical and biochemical characteristics of the study group are shown in table 4.1 
Twenty-one children completed the study. One child received a renal transplant and three 
were unable to tolerate the L-arginine due to unpleasant taste in two and nausea in one.
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Mean value ±SD
Age (years) 11.5 ±3
Sex 11:10
Ht (cms) 142.4±20.9
Weight (Kg) 40.3±15.8
Systolic/Diastolic BP (mmHg) 
GFR (nr 80-120 mls/min/1.73m2) 27.4±13.2
113±14/65±8
Serum creatinine (nr 30-102 pmol/1) 258+210
L-arginine (nr 40-120jxmol/l) 79±20.2
Serum total cholesterol 4.95+1.16
(nr 3.1-5.4 mmol/1)
Serum triglycerides (nr 0.4-1.4mmol/l) 1.5±0.54
Table 4.1: Physical and biochemical characteristics at entry o f the 21 children who 
completed the L-arginine study. The normal range (nr) is given where appropriate.
4.4.2 Effect of L-arginine on biochemistry (Table 4.2)
Group mean baseline levels of L-arginine were normal and no single value was below the 
lower limit. The dose of L-arginine used produced a significant rise in serum levels during 
the treatment phase when dosing regimen were pooled (p<0.001) compared with placebo 
(p=0.82). There was no significant difference in the post treatment levels of L-arginine on 
either dosing regimen. In the treatment phase versus placebo phase a rise in urea (change in
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urea 3.92±4.94 versus 0.85±2.68 mmols/1, p=0.015), a fall in bicarbonate (change in 
bicarbonate -3.05±3.84 versus 0.43±2.42 mmol/1 p=0.006), but no significant change in 
creatinine (p=0.87) were noted. All these values returned to baseline during the washout 
period for those who received L-arginine first.
Baseline Post L- 
arginine
Baseline Post
placebo
Change on 
L-arginine
Change on 
placebo
Urea 12.2 16.1 11.6 12.5 3.9 0.9 0.015
(nr 2.2-5.7 17.8 111.1 16.0 17.4 14.9 12.7
mmol/1)
Bicarbonate 22 19 22 23 -3. 0.4 0.006
(nr 20-26 13 13 12 12 14 12.4
mmol/1)
Creatinine 256 270 254 270 14 15 ns
(nr 0-120 1215 1233 1210 1234 142 131
pmol/1)
Table 4.2: Effect of L-arginine supplementation on renal chemistry. Data are expressed as 
mean±SD. P values for change on L-arginine v change on placebo.
4.4.3 Lipid analysis (Table 4.3)
Baseline total cholesterols were normal but triglycerides were elevated. There was a 
significant fall in TGs on treatment versus placebo (-0.0610.54 versus 0.1910.57 mmol/1, 
p=0.005) otherwise lipid profiles remained unchanged.
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4.4.4 Oxidative stress (Table 4.3)
A highly significant fall in total antioxidant activity of the serum was noted during the 
treatment period versus the placebo phase (-41 ±30 versus 16±54 microM trolox Eq, 
p<0.001). LDL lag times (a measure of the susceptibility o f LDL to oxidation) and 
antibodies to oxidised LDL were above the normal range for adults at baseline and there 
was no significant change with treatment. There was no effect of L-arginine on the ratio of 
low density to high density LDL or lipid peroxides.
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Baseline Post L- 
arginine
Baseline Post
placebo
Change on 
L-arginine
Change
on
placebo
Antibodies to 
oxidised LDL 
(n<250 mU/ml)
631
±501
579
±468
609
±406
562
±478
-23
±72
-47
±91
ns
LDL Lag times 
(n >60 mins)
87±19 83±21 89±17 89±20 0.2±18 0.5±23 ns
Lipid peroxides 
(pMol)
17.3
±21.2
16.6
±24
13.7
±23.2
22.9
±34.5
-0.7
±13.9
9.2
±30.5
ns
Antioxidant 
activity 
(n>440pM 
trolox Eq)
250±97 202±84 226±90 242±98 -41 ±30 16±54 <0.001
Lipoprotein
ratios
5.46
±3.43
6.57
±4.58
7.37
±6.0
6.46
±5.7
1.62
±5.45
-0.9
±7.53
ns
TC (n 3.1-5.4 
mmol/1)
4.8 ±1.3 4.5±1.1 4.9±1.0 4.8±0.9 -0.1 ±0.7 -0.2±0.5 ns
TG (n 0 .4-1 .4  
mmol/1)
1.53
±-0.53
1.45
±0.7
1.51
±0.55
1.96
±0.74
-0.06
±0.54
0.19
±0.57
0.005
HDL
(n>0.91 mmol/1)
1.3±0.4 1.2±0.4 1.1 ±0.4 1.2±0.3 -0.01±0.2 0.04±0.24 ns
LDL
(n<3.3mmol/l)
2.57
±1.2
2.45
±1.0
3.03
±0.85
2.72
±0.9
0.36
±1.75
-0.27
±0.62
ns
Table 4.3: Effect of L-arginine and placebo on lipid chemistry. Normal values (n) given 
where available. Data are expressed as mean±SD. P-value is given for change on L- 
arginine versus change on placebo.
4.4.5 Nitrate chemistry (Table 4. 4)
Plasma nitrate was elevated but plasma nitrite was normal at baseline. Plasma nitrated 
protein (nitrotyrosine) levels were increased significantly at entry to the study when 
compared with data available on normal children (0.126±0.07 v 0.02±0.007 Nitro-BSA 
equivs microgram/ml/mg protein, p<0.001). No significant changes in plasma nitrate or 
nitrite were observed with L-arginine treatment. Protein nitrotyrosine concentrations 
increased with L-arginine treatment but not significantly. There was no relationship 
between nitrotyrosine concentrations and those of nitrate and urea. Both L-arginine 
analogues ADMA and SDMA were elevated at baseline but there was no significant 
change on treatment or placebo.
A negative correlation between SDMA and GFR was the only relationship noted with 
r2=0.6 and p<0.05. Otherwise no significant relationships between NO metabolites and 
GFR were seen.
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Baseline Post L- 
arginine
Baseline Post
placebo
Change on L- Change on 
arginine placebo
Nitrates 
(n 32.1± 
4.3pMol)
68.6±63.1 67.2137.4 70.0155.6 62.9139.3 -1.13159.4 -7.12167.1 ns
Nitrites
(n 1.4±0.2pMol)
1.66±0.77 1.0910.54 1.7210.85 1.2912.2 -0.5710.8 -0.4312.47 ns
L-arginine* 
(n 80- 
120pMol/l)
82.9120 1791110 72.6119.7 70.7121.2 1041110 4114.5 <0.001
ADMA 
(n 0.7± 
0.1pMol/l)
1.3110.55 1.1910.60 0.9810.48 0.8410.41 -0.0210.91 0.024 
10.13
ns
SDMA 
(n 0.3±
0.1 pMol/1)
2.1611.41 1.8811.54 1.9111.37 1.9011.87 -0.5811.66 -0.4510.93 ns
Nitrotyrosines (n 
0.02±0.007 N T - 
BSA equivs, 
Microgram/ml/g)
0.1210.7 0.1610.11 0.1110.07 0.1210.06 0.0410.1 0.004 
10.05
ns
Table 4.4: Effect o f L-arginine on NO chemistry. Results are expressed as mean±SD. 
Normal values (n) for nitrates, nitrites, ADMA and SDMA are quoted from published data 
(2). * Result o f pooled doses. P-value is given for change on L-arginine versus change on 
placebo.
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4.4.6 Effect o f oral L-arginine on vasomotor function (Table 4.5)
There was no relationship between baseline FMD and any clinical and biochemical 
parameters measured. There was no effect of L-arginine on baseline arterial diameters, 
baseline blood flow or reactive hyperaemia (p=ns) on within subject analysis (hence no 
replication error), using the linear model repeated measures analysis.
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Brachial
Baseline Post L- 
arginine
Baseline Post
placebo
Change 
on L- 
arginine
Change
on
placebo
artery 3.28 3.28 3.28 3.24 0.007 -0.03 ns
diameter
(mm)
±0.62 ±0.69 ±0.63 ±0.69 ±0.15 ±0.18
Baseline flow 0.06 0.07 0.08 0.07 0.004 0.001 ns
(VTI, m) 
Maximum
±0.03 ±0.05 ±0.04 ±0.36 ±0.03 ±0.04
reactive
hyperaemia
(%)
529±208 471±243 489±333 480±249 -55.2±228 -8.76±364 ns
FMD (%) 
Systolic
7.94
±2.26
7.80
±2.95
8.2
±2.81
8.24
±3.12
0.06
±2.4
-0.14
±3.23
ns
blood
pressure
(mmHg)
Diastolic
113±14 107±11 112±15 111±16 -4.2±6.5 1±11.8 ns
blood
pressure
(mmHg)
64±10 61 ±10 63±I 0 65±9 -3.3±10.4 3.3±15.8 ns
Table 4.5: Vascular responses to L-arginine and placebo. Data are expressed as mean ±SD.
Flow mediated dilatation (Endothelial dependent dilatation) (Figure 4.1)
No significant difference in the change in flow mediated dilatation during the treatment 
phase versus the placebo phase was noted (p=0.84).
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Response to GTN (Endothelial independent dilatation) (Figure 4.1)
No significant difference in the change in response to GTN during the treatment phase 
versus the placebo phase was noted (p=0.2).
There was no significant change in resting heart rate, supine blood pressure during 
treatment or placebo phase suggesting that there was no haemodynamic effect of the L- 
arginine.
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Figure 4.1: FMD pre and post treatment with L-arginine and placebo. P=ns for group 
means.
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4.5 Discussion
This study has shown that oral supplementation with L-arginine did not improve brachial 
artery FMD, a measure of endothelial derived NO bioavailability, in children with CRT, 
despite achieving plasma levels of twice normal. Indeed, it would not have been possible 
to increase the dose any further as the children developed a significant increase in plasma 
urea, a fall in venous bicarbonate and a fall in total antioxidant activity.
The biological activity o f NO is impaired in CRF (114) which leads to reduced vascular 
relaxation, increased platelet aggregation, increased leucocyte adhesion and smooth muscle 
proliferation all processes which precede the formation of atherosclerotic plaques. L- 
arginine is the substrate for NO synthase and has been shown to increase endothelial 
function in animal models and in clinical studies of subjects with hypercholesterolaemia 
and coronary artery disease (150,151,152,155). I hypothesised that L-arginine 
supplementation in children with CRF might increase NO bioavailability by 3 main 
mechanisms: firstly by correcting a possible substrate deficiency; secondly by reducing the 
effect of endogenous inhibitors such as ADMA, known to be elevated in CRF; and thirdly 
by overcoming increased oxidative inactivation. Substrate deficiency was not 
demonstrated, as baseline serum L-arginine levels were normal. However, intracellular 
levels may not correlate with serum levels in CRF, as elevated levels of oxidised LDL 
(which are present in CRF) are associated with defective cellular transport for L-arginine 
(230).
L-arginine supplementation might overcome the effect of elevated methylated analogues,
ADMA and SDMA in CRF. ADMA is an inhibitor of eNOS (86) and although SDMA is
not a direct inhibitor it competes with the cationic amino acid transporter in the endothelial
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cell membrane (231) and therefore could heighten any intracellular arginine deficiency. In 
these children, we found both SDMA and ADMA were elevated at baseline when 
compared with previously published data in children (3). Levels were, however, not as 
high as those previously reported in adults with CRF (85, 86). The modest elevation of 
ADMA in this study group may have contributed to the lack o f vascular benefit seen with 
L-arginine supplementation. There was, however, no correlation between the response of 
FMD and levels of ADMA or those of L-arginine.
Markers of oxidative stress (antibodies to oxidised LDL, antioxidant activity) were 
elevated in this study. Increased oxidative stress might be responsible for reducing NO 
bioavailability by conversion of NO to nitrate, nitrate, and peroxynitrite (a potent cytotoxic 
agent) by superoxide. L-arginine supplementation could overcome this as in vitro studies 
have shown that L-arginine supplementation prevents preferential superoxide production in 
endothelial cells exposed to near physiological levels of oxidised-LDL (84). In these CRF 
children, there was no biochemical evidence of increased NO production (nitrate and 
nitrite levels remained unchanged) despite a doubling of the L-arginine levels. In view of 
the unrestricted diet this observation should be interpreted with caution. De Nicola et al 
achieved similar L-arginine levels in adult CRF patients with oral supplementation and 
were also unable to demonstrate enhanced NO production by measuring urinary 
cyclicGMP (intracellular mediator of NO). It is possible that important co-factors for 
eNOS such as tetrahydrobiopterin may have been deficient in the patients in this study 
(223). Under these conditions, NOS preferentially reduces molecular oxygen to superoxide 
even in the presence of adequate substrate concentrations. L-arginine at the dose used had 
adverse metabolic effects including elevated urea and extra cellular acidosis. These could 
have affected pH dependent signaling pathways and, therefore, eNOS activity. There was,
however, no correlation between these fully reversible effects and endothelial function.
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The reduction in total antioxidant activity of the serum suggests that increased oxidant 
stress was generated during the treatment phase.
L-arginine supplementation in this group of children with CRT did not improve endothelial 
function. Oral supplementation at a dose producing a two-fold rise in serum levels resulted 
in adverse metabolic sequelae in several children, and may have contributed to the negative 
outcome. Investigation into other mechanisms of impaired vascular biology in CRF is 
required.
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Chapter Five 
Folic acid study
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5.1 Original hypothesis
Dietary supplementation with folic acid reduces homocysteine levels and improves large 
vessel endothelium-dependent dilatation.
5.2 Introduction
In CRF, homocysteine is also an independent risk factor (99) for cardiovascular disease 
and in dialysis patients, hyperhomocysteinaemia is more prevalent than traditional 
cardiovascular risk factors (100). Homocysteine may, therefore, be contributing to 
aggressive “accelerated atherosclerosis” in CRF. In vitro and in vivo studies suggest that 
homocysteine causes endothelial dysfunction either directly or via intermediate reactions 
increasing oxidised LDL levels (101,102).
Folic acid has been shown to lower homocysteine levels in several populations and can 
improve endothelial function (163-166). In CRF there appears to be relative resistance to 
folic acid, but supplementation in adults with doses of 5-15mg per day can decrease 
homocysteine levels by as much as 40-50% (165). The effect on endothelial function has 
however been less impressive (175-177).
In this study high-resolution ultrasound was used to study the effect of folic acid 
supplementation on homocysteine and vascular function in children with moderate to 
severe CRF. Children were selected specifically both to reduce the influence of 
confounding factors and thus provide a clinical model of uraemic influences on the arterial 
wall, and to determine whether early intervention might have greater vascular benefits than 
those seen in adults.
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5.3 Subjects and methods
5.3.1 Subjects
Twenty-five children (11 girls and 14 boys, mean age 12±3 years (range 7-17)) with CRF 
(GFR <50ml/min/1.73m2) were recruited from the outpatient department at Great Ormond 
St Hospital. Twenty-four had congenital structural and one acquired (cortical necrosis) 
causes of CRF (see Chapter 2.2). No child received folic acid supplementation or vitamins 
(apart from activated vitamin D) prior to the study.
5.3.2 Study design
I performed a randomised, placebo-controlled, double-blinded, crossover trial with two 
eight-week treatment periods separated by an eight-week washout period. Folic acid was 
given at a dose of 5mg/m2 surface area (Special products Ltd Addlestone, Surrey KT15 
ITU, who also prepared the placebo).
Children were evaluated at the start and end of each treatment period. At each visit, supine 
blood pressure was recorded, blood taken (after a 6 hour fast) and vascular function was 
assessed.
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5.3.3 Assessment o f  vascular function
Endothelial function was determined by recording the dilator response of the brachial 
artery to increase blood flow generated during reactive hyperaemia of the downstream 
forearm, flow mediated dilatation (FMD). The technique is as described earlier chapter 3 
section 3.2. Analysis was performed by an experienced vascular technician blinded to the 
phase of the study.
5.3.4 Laboratory assays
Full blood count, urea, creatinine, bicarbonate and electrolytes were measured. Fasting 
lipid analyses were performed for total cholesterol (TC), high-density lipoprotein (HDL) 
and triglycerides (TGs). Both very low-density lipoprotein (VLDL) cholesterol and LDL 
were calculated. LDL subfractions were measured using high-resolution polyacrylamide 
gel electrophoresis. LDL lag times, lipid peroxides and antioxidant activity were measured 
as described in chapter 3.
Serum and red cell folate levels were determined using radioimmunoassay (Abott IMx) 
with a normal range for serum folate of 2 to 20pg/l and red cell folate of 150 to 650pg/l. 
Plasma total (free and bound) homocysteine was measured using a competitive 
fluorescence polarization immunoassay (normal range 4.4 to 13.7pmol/l for adults) (Abbot 
IMx).
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Power calculations were as described in chapter 3. The primary study endpoint was the 
change in FMD (post-treatment value minus pre-treatment value) on folic acid and on 
placebo. The change on folic acid and placebo was compared by paired Student t tests.
In addition final FMD after folic acid and after placebo were compared using ANCOVA. 
All data were analysed for period and carry over effects. All descriptive data are expressed 
as group mean ± standard deviation and significance is interpreted as a p value<0.05.
5.4 Results
5.4.1 Baseline characteristics
The clinical and biochemical characteristics of the study group are shown in table 5.1. 
Twenty-three children completed the study. One child was transferred to peritoneal dialysis 
and one received a renal transplant.
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Mean value ±SD
Age (years) 11.5 ±3
Sex c?:5 13:10
Ht (cms) 144.3±17.9
Weight (Kg) 40.9±14.7
Systolic/Diastolic BP (mmHg) 110±10/67±9
GFR (nr 80-120 mls/min/1.73m2) 28.3±12.7
Serum creatinine (nr 30-102 pmol/1) 229±193
Total homocysteine (nr 4.4-13.7pmol/l) 9.85±3.57
Serum total cholesterol (nr 3.1-5.4 mmol/1) 4.74+1.05
Serum triglycerides (nr 0.4-1.4mmol/l) 1.66+0.65
Haemoglobin (nr 13-16g/dl) 12.8+1.49
Table 5.1: Physical and biochemical characteristics at entry of the 23 children who 
completed the folic acid study. Normal range (nr) given where appropriate
5.4.2 Effect of folic acid (Table 5.2)
There was no effect of folic acid on haemoglobin or renal function. At entry to the study, 
serum folate (13.7±3.58pg/l) and red cell folate levels (334±202pg/l) were normal. Folic 
acid produced a significant increase in both serum folate (11.7+4.25 to 635+519 pg/1 
p=0.001) and red cell folate (364+195 to 2891 ±2623 pg/1 p<0.001) levels during the 
treatment period.
During placebo, there was no change in serum or red cell folate levels when the placebo 
phase preceded the folic acid phase (13.6±4.6 to 10.68±5.76 and 348±244 to 351±127pg/l
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p=ns). However, in the children who received placebo after folic acid, the serum folate 
changed from 20±9.9 to 14.01±6.08pg/l (p=ns) and the red cell folate from 820±517 to 470 
±185pg/l (p=0.02) during the placebo phase. These post placebo levels were higher at the 
end of the study than at entry suggesting a carry over effect for red cell folate.
5.4.3 Homocysteine levels (Table 5.2)
Homocysteine levels at entry to the study were greater (9.85±3.57pmol/l) than published 
data on normal children. There was a significant fall in total homocysteine levels after folic 
acid (10.28±4.16 to 8.62±2.32 mol/1 p=0.03), but not in the placebo phase (9.02±2.19 to 
9.84±2.7pmol/l p=0.3).
5.4.4 Lipid analysis (Table 5.2)
Baseline total cholesterol levels were within the normal range (4.74±1.05mmol/l) and there 
was no significant change with treatment or placebo. Triglycerides were elevated above the 
normal range (1.66±0.65mmol/l) and were unchanged after folic acid or placebo. HDL and 
LDL cholesterol were within the normal range at baseline (1.36±0.36mmol/l (normal 
range, 0.93-1.94) and 2.7±0.8mmol/l (normal range, 1.63-3.63) respectively and did not 
change significantly with either treatment or placebo.
5.4.5 Oxidant stress (Table 5.2)
Baseline values for LDL lag times were within the normal range. There was a significant 
increase in LDL lag times after folic acid (58.4±18.7 to 68.1±25.9mins p=0.01) compared
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to placebo (62.8±17.4 to 63.2±13.3 mins p=0.92) suggesting that folic acid 
supplementation reduced susceptibility of LDL to oxidation. Ratios of low to high density 
LDL (25±37 to 24±34 p=ns) remained unchanged during treatment and placebo phases (22 
±32 to 30±36 p=ns) as did total serum antioxidant activity (204±80 to 208174 on treatment 
v 188165 to 216174 ptrolox Eq on placebo p=ns).
Baseline Post­
placebo
Baseline Post FA
SFA 
(nr 3-20 pmol/1)
17.018.9 12.416.0 ns 13.118.8 6351519 0.001
RCF
(nr 150-650pmol/l)
5961468 4051168 0.02 3641195 28911
2623
0.0004
Total 
homocysteine 
(nr 4.4-13.7 
pmol/l)
9.0212.19 9.8412.74 ns 10.2814.16 8.6212.32 0.03
Total Antioxidant 
activity 
(n 440 ptrolox Eq)
188166 216174 ns 203180 207174 ns
LDL lag times 
(n 60 mins)
62.8117 63.2113 ns 58.4118 68.4125 0.001
Table 5.2: Biochemical responses to folic acid (FA) and placebo. Results are given as 
meanlSD. Normal ranges (nr) in brackets.
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5.4.6 Effect o f folic acid on vasomotor function (Figure 5.1)
There was no significant change in baseline arterial diameter, baseline arterial flow or peak 
reactive hyperaemia after folic acid or placebo (table 5.3).
Endothelial dependent dilatation (FMD)
A significant improvement in FMD, expressed as percentage and absolute change in vessel 
diameter (7.21±2.81 to 8.47±3.01% p=0.036 and 0.21710.106 to 0.25210.08lcms p=0.47) 
was seen after folic acid, which was not seen after placebo (8.2013.41 to 8.8014.01% 
p=0.44 and 0.24410.102 to 0.27610.104cms p=0.14). There was, however, no statistically 
significant difference in post-treatment FMD after placebo or folic acid (p=ns). Mean time 
of maximum dilatation after cuff release was not significantly different before or after 
treatment phases (pre-placebo 54±16 seconds, pre-folic acid 59=4=13 seconds, post-placebo 
65±19 seconds, post-folic acid 66±17 seconds). No carry over or period effect on FMD 
was detected (p=0.2 and 0.17 respectively).
Endothelial independent dilatation (GTN)
There was no significant change in response to GTN on either folic acid (12.5916.5 to 
11.5815.39% p=0.28 and 0.37410.136 to 0.3510.129cms p=0.4) or placebo (12.9315.71 to 
13.7516.46% p=0.32 and 0.39010.119 to 0.40410.170cms p=0.5).
There was no significant change in resting heart rate or supine blood pressure after folic 
acid or placebo.
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Baseline Post-placebo Baseline Post FA
FMD (%) 8.2±3.42 8.80±4.01 ns 7.21±2.8 8.49±3.02 0.036
FMD (cms) 0.244 0.276 ns 0.217 0.252 0.047
±0.102 ±0.104 ±0.106 ±0.081
GTN (%) 12.93±5.71 13.75±6.46 ns 12.59±6.53 11.58±5.39 ns
GTN (cms) 0.390 0.404 ns 0.374 0.350 ns
±0.119 ±0.170 ±0.136 ±0.129
Arterial diameter 3.11±0.57 3.18±0.59 ns 3.13±0.56 3.13±0.58 ns
(mm)
Resting blood 0.058±0.03 0.072±0.03 ns 0.065±0.04 0.074±0.04 ns
flow (VTI, m)
Peak reactive 680±540 464±233 ns 488±221 494±232 ns
hyperaemia (%)
Table 5.3: Vascular responses to folic acid (FA) and placebo. Results are given as m eant 
SD.
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Change in mean (±SEM) brachial artery dilatation (■= GTN p=ns, A=FMD p=0.036) on 
folic acid.
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Figure 5.1: Changes in mean brachial artery dilatation in response to flow (FMD and GTN) 
on folic acid and placebo
5.5 Discussion
This study shows that in children with CRF, supplementation with high dose folic acid for 
8 weeks results in reduction in homocysteine levels, decrease in LDL susceptibility to 
oxidation and improvement in endothelial function. These encouraging findings contrast 
with the disappointing effects of folic acid supplementation on vascular function in adults 
with renal disease.
Homocysteine levels are consistently elevated in adults with CRF and this has been 
suggested to play a role in the pathogenesis of atherosclerosis especially in view of its 
strong association with death from vascular disease in the non-uraemic population (95, 96, 
97, 98). A high prevalence of other risk factors exists in CRF but an independent 
association has been found between elevated total homocysteine levels and the risk of 
myocardial infarction (9). The data on homocysteine in children is limited. Lilien et al (93) 
reported elevated total homocysteine levels (12.6 ±5.2 v 8.2±3.3pmol/l p=0.004) in CRF 
children compared to controls. Total homocysteine levels at entry to our study 
(9.85±3.57pmol/l) were also elevated in comparison to these controls.
Homocysteine levels can be lowered using folic acid. This increases tissue methylation of 
homocysteine to form methionine in both uraemic and non-uraemic individuals, even in 
the presence of normal folate levels. Studies in adults with hyperhomocysteinaemia and 
hypercholesterolaemia have shown improvement in endothelial function as a consequence 
of lowering total homocysteine using folic acid (166,167,168). Similar studies in CRF have 
been disappointing. In both CRF and those on dialysis, no improvement in endothelial
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function has been demonstrated despite significant reductions in homocysteine. 
Thambyrajah et al (175) published a prospective double-blind trial in which 100 adults 
with a mean GFR of 30mls/min and a baseline total homocysteine of 20.1pmol/l were 
randomised to either folic acid or placebo. They achieved mean serum folate levels of 
39pg/l and red cell folate levels of 739pmol/l with 5mg of folic acid for 12 weeks. These 
values were lower than those achieved in this study. No improvement in endothelial 
function (using FMD) was seen despite a significant reduction in total homocysteine. Van 
Guldener et al (175) treated 30 adults on peritoneal dialysis for 12 weeks with 5 mg folic 
acid alone or together with 4g betaine (an additional co-factor) followed by 1 or 5 mg folic 
acid for 40 weeks. Total homocysteine levels were grossly elevated (42.6pmol/l) at the 
beginning of the study and normalised in 40% of patients without any improvement in 
FMD. In a further attempt to demonstrate long-term clinical benefit from folic acid 
administration, no improvement in endothelial function was seen after 52 weeks in adult 
haemodialysis patients, despite a significant reduction in homocysteine levels (177). 
Similarly in another population of adults on haemodialysis, carotid artery distensibility and 
compliance did not change after folic acid supplementation (232). The explanation for 
these largely negative studies may be due to the particularly aggressive complex nature of 
the vascular disease, the inability to normalise homocysteine levels in CRF (165,233), 
abnormal folate metabolism (234) or inadequate folate supplementation.
The dose of folic acid in this study produced serum and red cell folate levels higher than in
most published clinical intervention studies on CRF patients in the literature, in which
endothelial function was the primary endpoint. Variations between lmg and 60mg daily
have been used in the renal adult literature with no extra benefit on homocysteine levels
conferred by the higher doses. Duration of treatment in adult studies varied from 4 weeks
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to 52 weeks with the maximum effect on homocysteine seen in the first two weeks and no 
further lowering despite increasing doses of folic acid (233)
At the end of the folic acid treatment period homocysteine levels had fallen significantly. 
There was an 8-week washout period between the treatment phases. Analysis of serum and 
red cell folic acid levels showed that the subjects who received placebo after the active 
phase had a fall in red cell folate levels. This implies that there was a “carry over” from the 
active phase and that ideally the washout period could have been longer. There was, 
however, no carry over effect on homocysteine levels.
There was a significant improvement in FMD during the folic acid treatment phase without 
change in response to GTN suggesting a beneficial effect of folic acid on endothelial 
function after eight weeks of treatment. It should, however, be noted that the final FMD 
after placebo and active phases were not significantly different. These findings must 
therefore be interpreted with caution and a longer-term trial may be warranted.
The mechanism by which homocysteine exerts its toxic affect on the endothelium is
thought principally to be due to the generation of free radical species (101). In
experimental hyperhomocysteinaemia induced by methionine infusion in volunteers,
vitamin C improved endothelial function (102). In this study, there was a significant fall in
total homocysteine levels with folic acid in parallel with an increase in LDL resistance to
oxidation, through measurement of lag times. Total antioxidant activity was also measured
but no significant change was noted. Thus increasing the resistance of LDL oxidation
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might play an important role in the improvement in endothelial function, as oxidised-LDL 
is a potent vascular toxin. Alternatively folate may improve endothelial function via 
endogenous regeneration of tetrahydrobiopterin an essential co-factor in NO production or 
through a direct antioxidant effect as shown in vitro (235, 174).
Folic acid is safe, lowers homocysteine, reduces LDL susceptibility to oxidation and may 
improve endothelial biology relevant to the development of atherosclerosis. Long-term 
benefits require further study.
I l l
Chapter Six 
Haemodialysis study
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6.1 Original Hypothesis
Haemodialysis improves large vessel endothelium-dependent dilatation by lowering 
homocysteine levels, removing inhibitors of NO synthesis, reducing oxidative stress and/or 
removing free radicals.
6.2 Introduction
Although the aim of management for children in end-stage renal disease (ESRD) is 
transplantation, for many periods of dialysis are necessary. It has been postulated that the 
process of haemodialysis may, in itself, be atherogenic (236, 237). One mechanism for this 
may be through reduced bioavailability of NO as a result of increased oxidant stress 
generated by the dialysis process (201, 238, 239). NO is anti-atherogenic and is produced 
by vascular endothelium in response to physical and chemical stimuli. Damage to the 
endothelium, an established marker of early atherogenesis, decreases NO production which 
can be assessed by measurement of endothelial dependent flow mediated blood vessel 
dilatation using high resolution ultrasound (see chapter 1.5).
There is, however, conflicting evidence regarding the acute effect of haemodialysis on 
endothelial function; two studies have shown the process to have a beneficial effect (159, 
240) and another has shown an adverse effect (201). All these studies were in adults. To 
date the acute effect o f haemodialysis in children has not been investigated. Reasons for 
the differing results may be that cardiovascular disease was already established in the 
patients or that the fluid shifts that occurred during dialysis influenced the results.
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It is important to establish whether haemodialysis has an adverse effect on the endothelium 
and, if so, the mechanism whereby this occurs, in order to determine appropriate 
preventative therapies. Many children continue to produce urine and do not require fluid 
removal during the haemodialysis process, thereby removing the potential effect of large 
changes in extravascular fluid volume on blood pressure and endothelial function making 
results easier to interpret.
Therefore, endothelial function was assessed before and after a session of euvolaemic 
haemodialysis in a small group of children. In addition to measuring dialysis adequacy 
changes in oxidant stress and NO metabolites were measured.
6.3 Subjects and methods
6.3.1 Patients
Seven stable children receiving eulovaemic haemodialysis at Great Ormond St Hospital 
were entered into the study. Exclusion criteria were age <7 years (to ensure cooperation 
with the study), CRT of inflammatory cause, diabetes, arterio-venous fistulae in both arms, 
significant arterial/venous stenoses in proximal blood vessels, concurrent medication with 
immunosuppressants, and those with inter-dialytic fluid gains. The dialyser membranes 
used were all semi synthetic and biocompatible, Cobe from Gambro USA (haemophane) 
and Nipro FP 70 from Nipromedical Corporation Japan (triacetate cellulose and diacetate 
cellulose).
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6.3.2 Assessment o f conduit artery endothelial function.
Endothelial function was determined by recording the dilator response of the brachial 
artery to increase blood flow generated during reactive hyperaemia of the downstream 
forearm flow mediated dilatation (FMD), as discussed in Chapter 3, section 2.
6.3.4 Protocol
Blood pressure and endothelial function was assessed at baseline (predialysis), and at 1 
hour, 3 hours and 5 hours post dialysis using the same segment of brachial artery. Blood 
was drawn predialysis and at 1 hour post dialysis. The subjects’ weights pre and post 
dialysis were recorded.
6.3.5 Biochemical measurements
Blood samples were taken for urea, creatinine, venous bicarbonate, haemoglobin, C- 
reactive protein (CRP), folic acid, nitrotyrosines, total antioxidant activity of the serum and 
LDL lag times. Methodology as discussed in Chapter 3.
6.3.6 Statistics
All data are expressed as mean±SD and were checked for normal distribution. Group mean 
values pre-dialysis were compared with group mean values at each individual time point 
post dialysis using the paired Student t test. Significance was assumed at p<0.05.
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6.3 Results
6.3.1 Baseline characteristics
Six of the seven children completed all studies and one child elected to omit the 5 hour 
study. Their clinical characteristics are shown in table 6.1. All studies were performed 
without significant change in weight pre and post dialysis (Table 6.2)
Age (years) 12±3
Sex F:M 3:4
Aetiology of ESRF
Congenital dysplasia 6
Congenital nephrotic 1
Access
Tunneled line 6
AVF 1
Systolic BP (mmHg) 127 ± 19
Diastolic BP (mmHg) 73 ±10
KT/V 1.46 ±0.37
URR (%) 71 ±0.37
Dialyser
COBE 400 1
COBE 500 5
NIPRO FP70 1
Table 6.1: Patient characteristics
Baseline Post P value
Baseline flow (VTI, 0.07±0.02 0.09±0.02 ns
m)
Baseline diameter 3.26±0.6 3.32+0.6 ns
(mm)
Peak hyperaemia (%) 444±227 345±237 ns
FMD (%) 7.16±3.6 4.91+2.1 0.067
GTN (%) p 'O i+ 4^ 10.52±4.5 0.755
Systolic BP (mmHg) 126±18 128±22 ns
Diastolic BP (mmHg) 71 ±9 73±18 ns
Weight (Kg) 46.3±16 45.7±16 ns
Table 6.2: Physical characteristics pre and post dialysis. Expressed as means ± SD.
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6.3.2 Biochemistry and haematology results (table 6.3)
As expected, there was a fall in creatinine and urea post dialysis (p<0.001). No significant 
changes were noted in haemoglobin, serum folate, venous bicarbonate or C-reactive 
protein. The most striking change produced by haemodialysis was a marked reduction in 
total antioxidant activity of the serum (252±96 to 33±24 microM trolox Eq p=0.001). 
There was a small increase in LDL lag times, a marker of LDL resistance to oxidation (21± 
9 to 24±8 mins p=0.02). There was a tendency for nitrotyrosines to increase following
haemodialysis (0.034±0.03 to 0.065±0.05 p= 0.067) but this did not reach significance.
Pre dialysis Post dialysis P
Creatinine (nr 40-120 pmols/L) 754±122 289±97 <0.001
Urea (nr 4-7 mmol/L) 17±3.4 4.8±1.6 <0.001
Venous bicarbonate (25-35 mmol/L) 23±3.9 27±1.8 ns
Hb (nr 13-16g/dl) 9.7±1.2 9.4±1.2 ns
Serum folate (2 - 20pg/l) 12.7±5.6 13.611.5 ns
C-reactive Protein (<4 mg/L) 2.35±1.8 2.911.36 ns
Lag times (n 60mins) 21 ±9.4 2418.1 0.02
AOX (n=440 pM trolox Eq) 252±96 33124 0.001
Nitrotyrosines (nr 0.02-0.007BSA equivs pg/mg 0.04±0.03 0.0710.05 0.067
Table 6.3: Biochemical changes following dialysis expressed as mean ± SD
6.3.3 Vascular studies (Table 6.4)
In each child arterial diameter, blood pressure and heart rate did not differ significantly at 
any point in the study from that which was measured at baseline. In addition the stimulus 
of flow was not significantly different at any point in the study.
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Baseline study 1 hour post 3 hours post 5 hours post (n=6)
Baseline brachial 0.06810.02 0.08810.02 0.09610.04 0.08410.03
artery blood flow
(VTI, m)
Systolic BP 126118 128122 131125 122117
(mmHg) 
Diastolic BP 7119 73118 7618 73110
(mmHg)
Heart rate (per 90120 98132 88119 105132
min)
Reactive 4441227 3451238 3941215 284164
hyperaemia (%)
FMD (%) 7.1613.59 4.9412.07 § 5.0712.4 5.1115.14
GTN (%) 10.9617.41 10.5214.5 * 9.0714.46 11.0618.11
§ p=0.06
* p=0.75
Table 6.4: Vascular responses to haemodialysis in 7 subjects (except where n=6) at all time 
points. Data are expressed as mean±SD with no significant differences to baseline.
Endothelial dependent dilatation (FMD)
There was a trend for the FMD, and hence endothelial function, to worsen immediately 
post dialysis (7.16±3.59 to 4.94±2.07 % p=0.06), figures 6.1 and 6.2, without any 
significant change in the flow stimulus (reactive hyperaemia 4441227 to 3451238% p=ns) 
or the physical characteristics of the subject (table 6.2). Subsequently the FMD was 
restored at 3 and 5 hours post dialysis to values which were impaired, but not significantly 
so, from baseline (p=0.14 and p=0.37 respectively) (figure 6.2).
Endothelial independent dilatation (GTN)
There was no significant change in brachial artery response to GTN at any point compared 
with baseline (figures 6.1 and 6.2).
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Figure 6.1: Individual vascular responses to haemodialysis.
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Figure 6.2: Vascular response to haemodialysis (n=7). Data are expressed as group means 
± standard deviation.
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6.5 Discussion
This study has shown that endothelial dependent dilatation, and hence endothelial function, 
is likely to be adversely affected in children following a session of euvolaemic 
haemodialysis, at least over the first five hours post dialysis. Although this failed to reach 
significance, probably due to the small sample size. This effect could not be explained by 
differences in the stimulus for endothelial dependent dilatation (reactive hyperaemia) or 
altered smooth muscle response (endothelial independent dilatation).
Previous studies in adults have been inconsistent. Two have shown improvements in 
endothelial function (159,240) after haemodialysis whereas one has demonstrated a 
deterioration and another no change (201,241). However, in all but one of these studies 
(241) FMD was considerably reduced at the start, suggesting that vascular disease was 
already well established and, therefore, may not have been reversible. Furthermore, these 
studies might have been confounded by factors such as, fluid shifts, smoking and 
established arteriopathy, all of which we purposefully excluded in these children.
One way that the adverse effect of haemodialysis might operate is by interfering with NO 
production or metabolism. Here also conflicting results have been seen. Hand et al studied 
eight adult patients after haemodialysis using venodilatation. They postulated that the 
removal of inhibitors of NO synthase (L-arginine analogues) by haemodialysis increased 
NO bioavailability and resulted in the improvement in endothelial function (159). This 
theory was supported by similar improvements seen in the same patients with the infusion 
of L-arginine, the precursor of NO. Cross et al in 2001 also found a reduction in L-arginine
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analogues after haemodialysis but there was no correlation with FMD. In these studies NO 
bioavailability appeared increased as a consequence of the haemodialysis process (240).
However, in contrast, the pro-inflammatory effect of haemodialysis acts to increase 
oxidative stress. This is associated with inhibition of NO synthase and the inactivation of 
NO. Miyazaki (201) postulated that the deleterious effect of HD on endothelial function in 
the 12 adults they studied was a result of a pro-inflammatory reaction at the dialyser 
membrane generating reactive oxidant species, as the effect was reversed by a vitamin E 
coated dialyser. In addition, there was a significant rise in levels of oxidised LDL (oxLDL, 
a product of increase oxidative stress) in these patients, which correlated with FMD. This 
contradictory effect may have been due to the type of dialyser used, which was less 
biocompatible than in previous studies. This is supported by recent work from Kosch et al 
in adults who showed that only the less biocompatible cellulose dialyser membranes 
produced an adverse effect on endothelial function (FMD 9.4 ±2.1 to 7.4±1.8 % p 0.05) 
with no change seen using synthetic, biocompatible membranes (242).
However, despite the use of biocompatible membranes, I still found a highly significant 
reduction in total antioxidant activity of the serum and an increase in nitrotyrosines 
(products of increased oxidative stress) associated with the blunted FMD response. This 
suggests that antioxidants were removed and/or consumption of antioxidants was 
increased. This is in keeping with other studies that have shown elevated products of 
oxidative stress such as plasma oxLDL, lipid peroxides and reductions in serum 
antioxidants following a single session of haemodialysis (243, 244, 245, 246), in addition 
to a correlation between duration of dialysis and markers of oxidant stress (246). These
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effects are brought about at the dialysis membrane by the activation of polymorphs with 
the generation of reactive oxygen species and triggering of the inflammatory response 
(237). In this study there was no increase in CRP levels. This suggests that either the rise is 
delayed (ie blood samples taken too soon) or that the direct generation of reactive oxygen 
species, rather than inflammation was the main cause for the reduction in total antioxidant 
activity of the serum.
Although very low baseline values (compared with previously published data) of lag times 
of LDL were found, there was a significant but small increase following haemodialysis; 
i.e. LDL became more resistant to oxidation. LDL is particularly susceptible to oxidation 
(due to a high concentration of polyunsaturated fatty acids) and increases in levels of 
oxidized LDL have been demonstrated following a single session HD (243). Oxidised LDL 
is implicated in the formation of atherosclerotic plaques. LDL resists oxidation by virtue of 
lipid soluble antioxidants within the macromolecule, and it may be that in this study, 
haemodialysis resulted in acute concentration of lipid soluble antioxidants. On any count 
both pre and post dialysis lag times are both very low indicating a significant oxidant stress 
as the dominating phenomenon. This would account for the rise in oxidised LDL levels 
seen in other studies. Unfortunately we did not measure oxidised LDL levels.
Overall, the net effect of haemodialysis in this study would appear to be one of reduced 
NO bioavailability and endothelial dysfunction.
With the ever-increasing population of paediatric patients on haemodialysis these findings
are of clinical relevance. If the current methods of haemodialysis exacerbate the adverse
effects of renal failure on vascular biology, further research is required such that these
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effects could be prevented or retarded, thereby resulting in a subsequent reduction in 
cardiovascular mortality and morbidity.
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Chapter Seven 
Summary
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7.1 Main Observations
7.1.1 L-arginine Study
Results showed that oral supplementation with L-arginine for 4 weeks did not improve 
brachial artery endothelial function, despite achieving plasma levels of twice normal. It 
also demonstrated that oral L-arginine was unlikely to be a useful therapeutic tool in the 
form used due to the unpleasant taste and the adverse biochemical profile it produced. It 
would have been difficult to identity any direct positive benefit on NO bioavailability in 
the face o f the increased oxidant stress produced by its use.
7.1.2 Folic acid Study
This study showed that supplementation with high dose folic acid for eight weeks resulted 
in reduction in homocysteine levels, decrease in LDL susceptibility to oxidation and 
improvement in endothelial function.
However the results of this study should be interpreted with caution as the final FMD after 
placebo and active phases were not significantly different. The benefit seen perhaps 
because the pre treatment FMDs were different. Although no carry over effect was seen for 
homocysteine levels it is difficult to ignore the carry over effect seen for folic acid levels. 
The washout period was probably too short.
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7.1.3 Haemodialysis Study
This was a small study which showed that there was a trend for endothelial function to be 
adversely affected in children following a session of euvolaemic haemodialysis, at least 
over the first five hours post dialysis. This did not reach significance. However the fall in 
total antioxidant activity with a single session of haemodialysis did reach significance 
suggesting that the process of haemodialysis produces oxidant stress.
7.2 Future work
The principle of L-arginine supplementation is sound but its effect on the urea cycle makes 
it a useless therapeutic tool in renal failure in the chronic setting. The benefits of oral 
supplementation seen in both animal and human studies in high risk groups have not been 
conferred on the CRF population in either adults or children. Further clinical studies are 
probably not warranted.
More studies of folic acid supplementation are necessary, particularly long term to see if 
the benefit on endothelial function it produces improves cardiovascular outcome. There is 
a relative resistance to folic acid in CRF, which could perhaps be overcome by the addition 
of co-factors or active precursors.
The haemodialysis study should be extended, as certainly there was a trend for 
haemodialysis to result in a blunted FMD response. The sample size was however too 
small for the result to reach significance.
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If subsequent studies showed haemodialysis to have a significant adverse effect, more 
studies of the mechanisms and interventional studies should follow.
Clinical intervention studies not yet tried may be the use of statins, vitamins E and C and 
perhaps ACE inhibitors. Calcium phosphate metabolism is a key area.
The non-invasive technique of FMD lends itself well to the investigation of vascular 
pathology in children even in large-scale trials. The association between endothelial 
dysfunction and subsequent risk of cardiovascular mortality has been demonstrated 
prospectively in adults but not children. A long-term, large-scale, observational study of 
endothelial dysfunction associated with childhood onset CRF patients and its relationship 
to subsequent cardiovascular morbidity and mortality would be useful. If endothelial 
dysfunction, using FMD is confirmed as an independent predictive risk factor in children it 
could be used as a clinical tool.
If, as already suggested by epidemiological data, the paediatric population has relatively 
worse cardiovascular outcomes than adults, it is essential to pursue the interventional 
studies. If therapeutic intervention is available it could be used in conjunction with FMD 
before cardiovascular disease is apparent. The clinical implications are highly significant.
7.3 Conclusion
The increase in size of the stock of the paediatric renal patients on RRT by 37% in 10 years 
is of increasing concern. If mortality rates from cardiovascular disease for adults with CRF 
and RRT, from cardiovascular disease, far exceed that of the general population, what is 
the future for the paediatric population?
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Children with CRF and on RRT already have evidence of vascular disease and will be 
exposed to many more years of adverse chemistry making it likely that we will see 
problems occurring at an earlier age. Having survived their childhood years, death from 
cardiovascular disease in early adulthood may become inevitable.
Early intervention is the key, and this thesis concerns the development of primary 
prevention at a time when either adverse vascular biology could be prevented or reversed. 
This differentiates it from adult studies in which a high number of subjects have 
established vascular disease. Clinical intervention studies examining endothelial function 
in children with CRF, to my knowledge and at the time of writing had not previously been 
performed.
It is clear that factors other than those traditionally recognised, such as diabetes, 
hypertension, hypercholesterolaemia, and smoking are associated with the development of 
atherosclerotic disease in renal failure. If paediatric patients are to expect a reasonable 
prospect, care should also be taken in the management and investigation of the 
contributory factors discussed in this thesis.
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